Skip to main content

Jacob Bell

Senior Reporter |

Jacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. He can also be reached on Signal at realjacobbell.38.

Email [email protected]

chevron

Submit a tip to our team

chevron

1682 articles by Jacob Bell

Filter by month:

A brain biotech slumps even with ‘best case’ seizure data
Aug. 4, 2025
In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A
July 31, 2025
Atai backs away from schizophrenia drug after trial failure
July 28, 2025
In reversal, European regulators take positive view on Lilly Alzheimer’s drug
July 25, 2025
Alkermes narcolepsy drug headed for late-stage testing
July 21, 2025
Acadia CEO sets sights on ‘much more assertive’ deals to invigorate pipeline
July 2, 2025
Sodium channel blockers for pain: New opportunities after Vertex’s ‘watershed’ moment
July 1, 2025
Acadia’s ‘very bullish’ sales forecast restores some confidence on Wall Street
June 26, 2025
Compass’ big psychedelic study doesn’t impress investors
June 23, 2025
NewAmsterdam says cholesterol drug may also combat Alzheimer’s
June 9, 2025
Biotech funding plummets as Trump policies unnerve investors: Jefferies
June 4, 2025
Sanofi to acquire Blueprint for up to $9.5B
June 2, 2025
Lilly to buy pain drug developer SiteOne, challenging Vertex
May 27, 2025
Sanofi gains experimental Alzheimer’s drug through Vigil buyout
May 22, 2025
BioMarin to buy rare disease drugmaker Inozyme for $270M
May 16, 2025
FDA delays approval decision for Biohaven rare disease drug
May 15, 2025
Galapagos backtracks on planned split
May 13, 2025
Viatris’ new form of old pain drug scores in large trials
May 8, 2025
Facing ‘uncertainty on steroids,’ biotech dealmakers tread more cautiously
May 6, 2025
AstraZeneca quietly exits neuroscience
May 1, 2025
Biohaven stock slides on withdrawal of European marketing application
April 25, 2025
Bristol Myers says schizophrenia drug launch ‘off to a solid start’
April 24, 2025
Bristol Myers’ prized schizophrenia drug stumbles in testing
April 23, 2025
Former Neumora CEO to lead Galapagos spinout
April 22, 2025
New research kindles excitement around stem cell therapies for Parkinson’s
April 16, 2025
GSK targets neurodegenerative diseases with latest licensing deal
April 7, 2025
M&A recap: Big pharma starts the year mostly avoiding billion-dollar deals
April 4, 2025
FDA approves first-of-its-kind RNA drug for hemophilia
March 28, 2025
Lilly hits same Alzheimer’s roadblock in Europe as Eisai, Biogen
March 28, 2025
Biogen plots new global headquarters in Kendall Square
March 24, 2025
Novartis builds case for new SMA gene therapy
March 20, 2025
Latigo raises $150M to get non-opioid pain drugs through key tests
March 17, 2025
MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup
March 13, 2025
J&J scraps depression testing for potential blockbuster drug
March 7, 2025
Vertex’s new pain drug gets first coverage nod from major insurer
March 6, 2025
Tris to ask for approval of dual-acting pain drug
March 6, 2025
Biogen buys rights to Stoke’s rare epilepsy drug
Feb. 18, 2025
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public
Feb. 14, 2025
A brain biotech launches with Roche’s spare parts
Feb. 13, 2025
Bristol Myers gives first peek at closely watched launch of schizophrenia drug
Feb. 6, 2025
Shares of psychedelics biotech nearly double on depression data
Feb. 3, 2025
A new, non-opioid pain drug is here. Getting it to patients could be agony.
Jan. 31, 2025
Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research
Jan. 30, 2025
Roche’s new deals head tries to navigate a more ‘complicated’ and ‘expensive’ biotech world
Jan. 16, 2025
At JPM, Biogen CEO tries to take down the deal temperature
Jan. 15, 2025
Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street
Jan. 13, 2025
J&J to buy psychiatric drug developer Intra-Cellular for $14.6B
Jan. 13, 2025
ALS drugs from Denali, Calico come up short, marking setback for Healey trial
Jan. 7, 2025
Neumora plummets on depression drug data
Jan. 2, 2025
Roche sticks with Parkinson’s drug despite second study failure
Dec. 19, 2024
Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint
Dec. 19, 2024
A Vertex partner — and potential rival — secures $100M to develop non-opioid pain drugs
Dec. 18, 2024
CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug
Dec. 13, 2024
UniQure shares soar on chance of speedy approval for Huntington’s therapy
Dec. 10, 2024
GSK taps a startup for shot at Alzheimer’s drug
Dec. 5, 2024
Dewpoint, Mitsubishi partner on ALS drug in deal worth up to $480M
Dec. 4, 2024
Novartis wagers billions of dollars on PTC Huntington’s drug
Dec. 2, 2024
How Intra-Cellular surprised Wall Street by breaking character
Nov. 27, 2024
Roche to buy cell therapy developer Poseida for $1B
Nov. 26, 2024
Alector turns to layoffs as Alzheimer’s drug fails
Nov. 26, 2024
Novartis wagers more than $1B on gene therapies for the nervous system
Nov. 21, 2024
Sage’s string of research failures continues
Nov. 20, 2024
How a Biogen drug set the stage for a new biotech targeting ALS
Nov. 15, 2024
Eisai wins over European regulators on Alzheimer’s drug Leqembi
Nov. 14, 2024
Biotech investors, including Third Rock, pump $100M into a startup’s genetic medicine for ALS
Nov. 12, 2024
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Nov. 11, 2024
AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies
Nov. 11, 2024
Athira exploring strategic alternatives after Alzheimer’s failure
Nov. 8, 2024
Investors put $115M into Axonis amid revived interest in brain drugs
Oct. 30, 2024
Biogen optimistic as new products gain traction
Oct. 30, 2024
AbbVie to acquire a J&J-backed brain drugmaker for $1.4B
Oct. 28, 2024
Alto hits new low as depression drug flunks key test
Oct. 23, 2024
PureTech thinks the ‘hub-and-spoke’ startup model is still a good bet. If only investors agreed.
Oct. 21, 2024
Brain drug developer Seaport raises another $225M
Oct. 21, 2024
After rejections, AbbVie secures approval for Parkinson’s drug
Oct. 17, 2024
Lundbeck to buy brain drug developer Longboard for $2.6B
Oct. 14, 2024
Sanofi may have found a buyer for its consumer health business
Oct. 11, 2024
Sage continues downslide as Alzheimer’s study fails
Oct. 8, 2024
Sanofi’s rare disease drug finds yet another home
Oct. 4, 2024
Approval in hand, Bristol Myers sets out to sell first-of-its-kind schizophrenia drug
Sept. 26, 2024
Struggling 2Seventy scraps a key cancer study
Sept. 25, 2024
Biogen, UCB get the lupus data they’ve waited two decades for
Sept. 24, 2024
After setback, Biohaven to seek approval of neurological disorder drug
Sept. 23, 2024
Investors are waking up to Centessa’s sleepiness drug
Sept. 10, 2024
Neurocrine’s mixed schizophrenia data disappoint Wall Street
Aug. 28, 2024
BioMarin taps Amgen, Roche vets in executive reshuffle
Aug. 21, 2024
Lykos to cut 75% of staff after FDA rejection of MDMA-based therapy
Aug. 15, 2024
Incyte builds out its arsenal of post-transplant drugs
Aug. 15, 2024
Following FDA rejection, a journal retracts papers on MDMA-assisted therapy
Aug. 12, 2024
In tone-setting verdict, FDA rejects MDMA as a therapy aid for PTSD
Aug. 9, 2024
Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs
Aug. 6, 2024
As sales climb, Biogen ‘convinced’ the worst is over for Leqembi
Aug. 1, 2024
Leqembi voted down by European regulators
July 26, 2024
Sanofi’s immunology bet starts to pay off
July 25, 2024
Biogen, Sage tremor drug fails key trial
July 24, 2024
Ionis plots next steps for Angelman drug Biogen passed on
July 22, 2024
Asceneuron raises another $100M for Alzheimer’s drug development
July 16, 2024
Pfizer thinks it found its obesity pill
July 11, 2024
Amylyx, with GLP-1 buy, doubles down on blood sugar drugs
July 10, 2024
UniQure stock surges on data for Huntington’s gene therapy
July 9, 2024
Lilly to buy Morphic in $3B bet on inflammation drug
July 8, 2024
CureVac cuts jobs, licenses out vaccines to GSK
July 3, 2024
These microscopic tunnels are a goldmine for new medicines
June 27, 2024
Syncona melds two gene therapy biotechs for better shot at new nervous system treatments
June 17, 2024
Lilly Alzheimer’s drug gets unanimous backing of FDA panel
June 10, 2024
After ‘sobering’ FDA panel, psychedelics supporters wonder what’s next
June 7, 2024
FDA panel votes against MDMA therapy for PTSD, citing muddy data and safety concerns
June 4, 2024
FDA staff outline shortcomings of Lykos data for MDMA therapy
May 31, 2024
Orna, a circular RNA specialist, acquires a buzzy startup
May 23, 2024
Forbion-backed biotech Progentos debuts with $65M for MS drug
May 20, 2024
Biogen, Ionis shelve ALS drug following study failure
May 16, 2024
Eisai sets new revenue target for Alzheimer’s drug Leqembi
May 15, 2024
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
May 13, 2024
FDA sets date for advisory meeting on Lilly’s closely watched Alzheimer’s drug
May 7, 2024
Gossamer sells rights to drug it hopes can rival a new Merck therapy
May 6, 2024
Reunion raises over $100M to build a better psychedelic drug
May 2, 2024
Deciphera to sell for $2.4B, adding to upswing in biopharma M&A
April 29, 2024
Biogen: Don’t expect any big acquisitions this year
April 24, 2024
Biogen to invest more in launch of Alzheimer’s drug Leqembi
April 24, 2024
Neurocrine scores surprise win with depression drug
April 23, 2024
Sage’s cognition drug fails in Parkinson’s study
April 17, 2024
Intra-Cellular builds case for depression drug with late-stage trial win
April 16, 2024
Neumora’s schizophrenia drug hit with clinical hold
April 15, 2024
Roche, Adaptimmune part ways on cell therapy research
April 12, 2024
PureTech launches Seaport, hoping to create Karuna 2.0
April 9, 2024
Psychiatry drugs finally have pharma’s attention. Can they keep it?
April 8, 2024
Amylyx to pull ALS drug from market in rare move
April 4, 2024
Paragon’s hub-and-spoke biotech model yields another reverse merger
April 3, 2024
Acorda files for bankruptcy, reveals asset sale plan
April 2, 2024
European study finds popular ALS drug ineffective
March 27, 2024
Axsome drug succeeds in narcolepsy symptoms trial
March 25, 2024
Acelyrin eye drug heads to late-stage testing after trial win
March 20, 2024
Engrail’s precision psychiatry drugs get more buy in from venture investors
March 19, 2024
Bristol Myers cell therapy wins first-of-its-kind approval
March 15, 2024
After surprise trial failure, ALS doctors brace for one less treatment option
March 12, 2024
Amylyx CEOs look for a path forward following major setback
March 11, 2024
Amylyx ALS drug fails crucial study, putting company’s future in doubt
March 8, 2024
NodThera says inflammation drug has positive effect in Parkinson’s
March 7, 2024
Gilead bets on ‘trispecifics’ in latest cancer drug deal
March 6, 2024
Bayer isn’t splitting up, for now
March 5, 2024
Cure Ventures backs a cell therapy startup targeting Parkinson’s
Feb. 29, 2024
Incannex says psilocybin therapy lowered anxiety in small study
Feb. 28, 2024
NGM to go private through deal with investment firm
Feb. 26, 2024
AbbVie’s Cerevel deal hits an uncommon roadblock
Feb. 20, 2024
Intellia, ReCode partner on genetic medicines for cystic fibrosis
Feb. 15, 2024
Biogen has a fuzzy line of sight on prized Alzheimer’s drug
Feb. 13, 2024
Takeda speeds narcolepsy drug to late-stage testing
Feb. 9, 2024
Neurona raises another $120M for brain disease cell therapies
Feb. 8, 2024
Eisai falls behind on Leqembi patient goal
Feb. 6, 2024
J&J says top drug prospect works across autoimmune disorders
Feb. 5, 2024
Biogen quits Aduhelm, handing back rights to original developer
Jan. 31, 2024
Karuna, Cerevel might be just the start of psychiatry drug M&A
Jan. 22, 2024
Biogen CEO sees progress in launch of Alzheimer’s drug Leqembi
Jan. 8, 2024
An unusual drugmaker raises north of $100M for ecstasy-based PTSD therapy
Jan. 5, 2024
10 clinical trials to watch in the first half of 2024
Jan. 2, 2024
Clene says its ALS drug data is not yet enough for FDA
Dec. 21, 2023
As ALS research booms, one treatment center finds itself in the spotlight
Dec. 20, 2023
Investors still aren’t sold on UniQure’s gene therapy for Huntington’s
Dec. 19, 2023
Amgen finds a new top scientist in Novartis veteran Bradner
Dec. 15, 2023
AbbVie to buy Cerevel in $8.7B bet on brain drugs
Dec. 6, 2023
Pharvaris shares spike as drug appears to prevent symptoms of rare disorder
Dec. 6, 2023
European regulators want to know more about the risks of GLP-1 drugs
Dec. 1, 2023
Bristol Myers pours $100M into RNA drugs for cardiovascular diseases
Nov. 28, 2023
Xenon drug misses main goal of depression study
Nov. 27, 2023
AstraZeneca creates digital health unit, with big-name partnerships already in place
Nov. 20, 2023
Biogen says growth is coming, but won’t specify when
Nov. 8, 2023
A brain-focused biotech raises $225M to develop drugs for schizophrenia, Parkinson’s
Oct. 30, 2023
Bristol Myers’ neuroscience research head explains the big pharma’s return to brain drugs
Oct. 27, 2023
Vertex gearing up for launch as sickle cell therapy review advances
Oct. 26, 2023
Eisai says new data could support more convenient form of Alzheimer’s drug Leqembi
Oct. 25, 2023
BrainStorm, after setbacks, withdraws approval application for ALS drug
Oct. 18, 2023
Roche is stuck on molecular glue
Oct. 17, 2023
Amylyx’s ALS drug knocked back again in Europe
Oct. 13, 2023
After summer slump, biotech M&A has a good week
Oct. 10, 2023
NIH funds research for three experimental ALS drugs
Oct. 6, 2023
AbbVie acquires Parkinson’s drug in latest biotech buyout
Oct. 5, 2023
Regeneron, Intellia target neurological diseases in expanded gene editing deal
Oct. 3, 2023
Novartis’ closely watched rare disease drug scores in kidney disorder
Oct. 2, 2023
Seagen’s cancer drug succeeds in ‘must-win’ trial
Sept. 22, 2023
FDA approves GSK’s new bone cancer drug, helping validate a billion-dollar bet
Sept. 18, 2023
New startup Arialys takes aim at the immune system, hoping to create neuropsychiatry drugs
Sept. 12, 2023
Alnylam says hypertension drug succeeded in mid-stage study
Sept. 7, 2023
Biogen, continuing executive revamp, finds a new research head
Sept. 6, 2023
FDA documents hint at ‘uphill battle’ for broad approval of Sage’s depression drug
Sept. 1, 2023
Sanofi appoints a venture investor to R&D head as executive team expands
Aug. 31, 2023
Bayer reports positive early data for Parkinson’s cell therapy
Aug. 28, 2023
FDA approves Novartis’ copycat of blockbuster Biogen drug
Aug. 25, 2023
J&J-backed startup raises another $150M for brain drug development
Aug. 23, 2023
FDA expands use of Neurocrine drug to Huntington’s patients
Aug. 21, 2023
Merck says drug acquired in $1B buyout scores in large kidney cancer study
Aug. 18, 2023
J&J grows cancer drug portfolio with newly approved bispecific
Aug. 10, 2023
Emergent to lay off around 400 in pivot away from contract manufacturing
Aug. 8, 2023
Sage considers cuts after FDA’s split decision on depression drug
Aug. 7, 2023
FDA approves Sage, Biogen drug for postpartum depression, but rejects wider use
Aug. 4, 2023
TG shares tumble following licensing deal for MS drug
Aug. 1, 2023
Idorsia warns of up to 500 layoffs as part of cost-cutting initiative
July 21, 2023
Sanofi, searching for new immune system drugs, partners with a young biotech
July 20, 2023
An Arch-backed biotech pushes its depression drug into late-stage testing
July 18, 2023
Lilly Alzheimer’s drug slowed disease by roughly half a year, new results show
July 17, 2023
Westlake raises $450M in latest biotech venture fund
July 17, 2023
Eisai’s Ivan Cheung, who oversaw Alzheimer’s drug success, to depart
July 11, 2023
FDA grants Eisai’s Leqembi full approval, opening door to wider use of Alzheimer’s drug
July 6, 2023
With FDA approval in hand, BioMarin lays out plan to sell $2.9M gene therapy
June 30, 2023
BioMarin finally secures FDA approval of hemophilia gene therapy
June 29, 2023
Lilly takes over partner working on cell therapies for diabetes
June 29, 2023
Sanofi chalks up another win for its immune system research
June 27, 2023
Biogen shareholders vote in favor of new board member
June 26, 2023
5 FDA decisions to watch in the third quarter
June 26, 2023
Amylyx’s ALS drug gets pushback from European regulators
June 23, 2023
Roivant reports more positive data for inflammation drug
June 22, 2023
UniQure stock tumbles on ‘confusing’ results for Huntington’s gene therapy
June 21, 2023
Coherus doubles down on immuno-oncology with latest deal
June 16, 2023
Biogen’s latest board shake-up includes potentially controversial pick
June 13, 2023
Built from biotech parts, Beacon launches with $120M to develop eye gene therapies
June 12, 2023
FDA panel backs full approval for Eisai, Biogen Alzheimer’s drug
June 9, 2023
Ahead of key meeting, FDA appears open to full approval of Alzheimer’s drug Leqembi
June 7, 2023
FDA sets advisory meeting date for Brainstorm’s ALS cell therapy
June 6, 2023
Biogen scraps late-stage study for Parkinson’s drug
June 5, 2023
Wave shelves ALS drug following trial setback
May 23, 2023
Ironwood to buy rare disease drugmaker in billion-dollar deal
May 22, 2023
Moderna reports ‘encouraging’ early data for one of its rare disease medicines
May 19, 2023
Mustang pares research, sells manufacturing plant to save money
May 18, 2023
PTC’s drug for PKU succeeds in late-stage clinical trial
May 17, 2023
A struggling biotech wraps its main assets into a new drug company
May 12, 2023
Amylyx’s ALS drug again surpasses Wall Street expectations
May 11, 2023
Alzheimer’s doctors see promise, limits in Lilly’s latest drug data
May 10, 2023
Lilly’s new Alzheimer’s data may both help and hinder rival Biogen
May 3, 2023
FDA approves new ALS medicine in precedent-setting decision
April 25, 2023
Biogen’s new strategy brings more pipeline cuts, but leaves deal options open
April 25, 2023
Apellis’ immune system drug hits a setback in ALS
April 21, 2023
Merck’s latest deal turns up the spotlight on immune system drugmakers
April 17, 2023
A biotech startup with big-name backers aims to create new cancer medicines
April 14, 2023
Biogen, aiming for a better Alzheimer’s therapy, licenses a Denali program
April 13, 2023
Novo’s latest deal targets cell therapy for diabetes, obesity
April 12, 2023
A new biotech wants to ease a bottleneck in cell and gene therapy production
April 11, 2023
Ginkgo grows its gene therapy offerings with StrideBio deal
April 5, 2023
Biogen taps a deals expert in latest C-suite appointment
April 4, 2023
5 FDA decisions to watch in the second quarter
April 3, 2023
Cytokinetics to end late-stage study of ALS drug
March 31, 2023
A brain drug developer joins a growing list of biotech layoffs
March 30, 2023
Intra-Cellular shares rise on depression study’s success
March 28, 2023
ALS drugmakers, encouraged by recent FDA feedback, set their sights on a key protein
March 27, 2023
FDA advisers support conditional clearance of Biogen’s ALS drug
March 22, 2023
FDA staff signal support for Biogen ALS drug, but highlight data hurdles
March 20, 2023
Karuna’s schizophrenia drug succeeds in a second late-stage trial
March 20, 2023
Amylyx’s ALS drug sales impress Wall Street
March 13, 2023
J&J-backed startup launches with $100M to build better brain drugs
March 7, 2023
Despite study setback, a biotech plans to push tremor drug into late-stage testing
March 3, 2023
Novo Nordisk to create Boston R&D hub
March 2, 2023
Following another trial failure, a brain biotech considers ‘strategic alternatives’
Feb. 28, 2023
Seagen reportedly in sales talks again, this time with Pfizer
Feb. 27, 2023
Novartis backs away from NASH, furthering its research revamp
Feb. 24, 2023
FDA approves Sanofi’s long-lasting hemophilia drug
Feb. 23, 2023
Moderna inks another gene editing deal
Feb. 22, 2023
With sales falling, Biogen’s new CEO says transformation is needed
Feb. 15, 2023
Sanofi R&D head John Reed leaves to take similar role at J&J
Feb. 13, 2023
Cigna restricts coverage of new ALS drug, deepening fears about access
Feb. 7, 2023
Eisai gives first glimpse into Alzheimer’s drug launch
Feb. 6, 2023
Karuna, hoping to find new brain drugs, buys up a shuttering biotech’s pipeline
Feb. 2, 2023
Novartis confirms it has stopped development of experimental Huntington’s drug
Feb. 1, 2023
UniQure nabs another gene therapy for ALS
Jan. 31, 2023
J&J, Legend’s cancer cell therapy has early success in key clinical trial
Jan. 27, 2023
Sales of J&J, Legend cell therapy plateau amid production challenges
Jan. 25, 2023
FDA to seek outside advice on Biogen’s ALS drug
Jan. 24, 2023
Why Wall Street shrugged at Lilly’s Alzheimer’s setback
Jan. 20, 2023
3 biotech executives on the year ahead: deals, drug pricing and the down market
Jan. 19, 2023
JPM23: Takeda tests Bristol Myers, Prime weighs spinoffs and Sanofi faces down a competitor
Jan. 11, 2023
JPM23: Califf on accelerated approvals, biotech startups’ looming cliff and an explanation from Editas
Jan. 10, 2023
JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies
Jan. 10, 2023
FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision
Jan. 6, 2023
Roivant reveals positive data for IBD drug, intensifying rivalry with Prometheus
Jan. 4, 2023
Gilead buys Tmunity, cozying up to a CAR-T pioneer
Dec. 20, 2022
Madrigal shares triple on positive NASH study results
Dec. 19, 2022
European regulators back hemophilia gene therapy
Dec. 16, 2022
For ALS patients, doctors, a new medicine reignites concerns about healthcare access
Dec. 15, 2022
Clovis files for bankruptcy
Dec. 12, 2022
Gilead buys into multiple myeloma cell therapy with Arcellx deal
Dec. 9, 2022
Vertex invests in a rare disease drug and its developer
Dec. 8, 2022
Prometheus shares soar on new data for inflammation drug
Dec. 7, 2022
Pfizer, Roivant set up new company around inflammation drug
Dec. 1, 2022
What to make of Eisai and Biogen’s Alzheimer’s drug results
Nov. 29, 2022
Axsome says drug eased Alzheimer’s symptom in positive study
Nov. 28, 2022
Narcan developer to be acquired by Indivior
Nov. 14, 2022
FDA declines to review Brainstorm’s ALS therapy
Nov. 11, 2022
Centerview grows role as go-to adviser for biopharma dealmaking
Nov. 8, 2022
Galapagos to cut 200 jobs amid research revamp
Nov. 4, 2022
Abeona to submit cell therapy for approval after positive results for skin disorder treatment
Nov. 3, 2022
String of gene therapy deals spurs cautious optimism on Wall Street
Nov. 1, 2022
Gilead, fueled by latest approval, sees CAR-T sales take off
Oct. 28, 2022
BioMarin to face FDA advisers before approval decision on hemophilia gene therapy
Oct. 27, 2022
For Biogen investors, company’s outlook rests on next Alzheimer’s drug
Oct. 25, 2022
Myovant agrees to sell after buyer ups price
Oct. 24, 2022
Lilly bets more than $600M on a gene therapy developer targeting hearing loss
Oct. 18, 2022
Biogen expects longer wait on ALS drug decision from FDA
Oct. 17, 2022
5 questions facing drugmakers as third quarter earnings begin
Oct. 17, 2022
Enliven to enter public markets through reverse merger with Imara
Oct. 14, 2022
BioMarin to lay off about 120 employees as part of restructuring plan
Oct. 7, 2022
A Versant-backed biotech emerges to take on ‘overlooked’ cancer targets
Oct. 6, 2022
Biogen, Denali begin late-stage testing of Parkinson’s drug
Oct. 3, 2022
5 FDA decisions to watch in the fourth quarter
Oct. 3, 2022
Amylyx sets ALS drug price at $158,000 per year, opening new debate on cost
Sept. 30, 2022
ALS drug approved by FDA in closely watched decision, marking win for patients, developer
Sept. 29, 2022
With little data to go on, experts question how useful Eisai, Biogen’s new Alzheimer’s drug will be
Sept. 29, 2022
Vertex given green light to seek US approval of CRISPR-based therapy
Sept. 27, 2022
Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug
Sept. 26, 2022
FDA advisers back Amylyx ALS drug, reversing earlier position
Sept. 7, 2022
Neurocrine, with latest deal, gets a foothold in Europe
Aug. 30, 2022
Incyte secures second approval for targeted cancer drug
Aug. 29, 2022
With European approval secured, BioMarin puts roughly $1.5M price tag on hemophilia gene therapy
Aug. 25, 2022
Backed by $40M, a biotech startup targets cancer with help from the immune system
Aug. 25, 2022
Next-generation RNA technologies: making longer-lasting drugs with a broader reach
Aug. 23, 2022
Gilead, with new results, doubles down on breast cancer drug
Aug. 16, 2022
Despite failed trial, Brainstorm asks FDA to approve ALS drug
Aug. 15, 2022
Karuna shares soar on schizophrenia drug results
Aug. 8, 2022
Amgen bets almost $4B on a biotech and its inflammation drugs
Aug. 4, 2022
Gilead, following cell therapy approval, impresses Wall Street with fast sales
Aug. 3, 2022
AbbVie, targeting a well-known protein family, expands a partnership into neuroscience
Aug. 2, 2022
Nuvation to cut workforce by 35% as it scraps lead drug program
Aug. 1, 2022
Novartis-linked startup launches with technology designed to remove ‘destroy’ tags on helpful proteins
July 28, 2022
FDA, in another test of its flexibility, agrees to review Biogen's closely watched ALS drug
July 26, 2022
With Aduhelm sidelined, Wall Street turns to Biogen's next Alzheimer's drug
July 20, 2022
FDA approves new vitiligo treatment, bolstering Incyte's dermatology business
July 19, 2022
Ultragenyx sells rare disease drug royalties to Canadian pension fund
July 15, 2022
Agios CEO to step down, handing role to veteran in rare disease drug sales
July 12, 2022
Vertex acquires another maker of potentially curative diabetes treatments
July 11, 2022
After a lengthy drought, could biotech M&A be on the upswing?
July 8, 2022
New analysis encourages Intercept to refile NASH drug for approval
July 7, 2022
In 'unusual' move, FDA to reconvene advisers for ALS drug review
July 5, 2022
10 clinical trials to watch in the second half of 2022
July 5, 2022
Blueprint secures access to more than $1B in funding through two new deals
June 30, 2022
5 FDA decisions to watch in the third quarter
June 29, 2022
Arch brings in another $3B for biotech startup investing
June 29, 2022
Jazz drug fails in late-stage study for multiple sclerosis
June 28, 2022
BioMarin's hemophilia gene therapy recommended for approval in Europe
June 24, 2022
Biogen, citing insurance challenges, shutters one of its Aduhelm studies
June 22, 2022
Galapagos, with latest deals, charts an unexpected journey to cell therapy
June 22, 2022
Roche Alzheimer's study fails in another setback to a long-tested hypothesis
June 16, 2022
With biotech in retreat, Third Rock raises $1B for life sciences investing
June 15, 2022
Amylyx's ALS drug gets approved in Canada
June 13, 2022
Vertex, CRISPR strengthen case for pioneering gene-editing treatment
June 11, 2022
Astellas, despite recent setbacks, opens $100M gene therapy plant
June 8, 2022
Amarin turns to job cuts as generics challenge its heart pill
June 6, 2022
Yumanity's days as an independent biotech come to a close
June 6, 2022
Detailed study data show modest benefit to Gilead breast cancer drug
June 4, 2022
Biohaven hits setback as it moves beyond migraine
May 23, 2022
AbbVie asks FDA to approve Parkinson’s treatment
May 20, 2022
Gilead, having resolved manufacturing issues, forges ahead with HIV drug
May 17, 2022
Agios to cut jobs as it moves away from exploratory research
May 16, 2022
FDA approves oral version of Mitsubishi's ALS drug
May 13, 2022
Moderna's finance head is out as former employer conducts investigation
May 11, 2022
Pfizer to acquire Biohaven in $11.6B bet on biotech's migraine drugs
May 10, 2022
Against a historic market downturn, Moma Therapeutics raises $150M for precision cancer research
May 10, 2022
Biogen, having scrapped Aduhelm, tries to convince investors of turnaround plan
May 4, 2022
Biogen CEO to step down as company pulls back from Alzheimer’s drug
May 3, 2022
A cancer biotech attracts another deep-pocketed partner in Gilead
May 2, 2022
AbbVie's first shot at Vertex misses, but it's not abandoning cystic fibrosis
April 29, 2022
After setbacks, a gene therapy company mulls a sale
April 28, 2022
Undeterred by gene therapy's struggles, a startup launches into a downturn
April 26, 2022
Biogen pulls European application for Aduhelm in another setback for the Alzheimer's drug
April 22, 2022
Seagen to expand, add jobs with new cancer drug factory
April 21, 2022
A promising cancer drug leads Regeneron to reconsider its aversion to M&A
April 19, 2022
Troubling data leads a biotech to pull its prized drug from market and FDA review
April 18, 2022
Editas CEO to step down in latest executive change-up
April 14, 2022
Halozyme, doubling down on a licensing strategy, buys a drug delivery biotech for nearly $1B
April 13, 2022
Regeneron, in search of an eye gene therapy, turns to a young biotech
April 6, 2022
FDA clears second Novartis plant for gene therapy manufacturing
April 5, 2022
Alnylam to wait longer for FDA verdict on latest RNA drug
April 4, 2022
Yet another gene therapy developer turns to layoffs
April 1, 2022
5 FDA decisions to watch in the second quarter
March 31, 2022
FDA advisers narrowly side against an experimental ALS drug, likely lowering its approval chances
March 30, 2022
How a long shot ALS drug came before the FDA
March 28, 2022
Al Sandrock takes on CEO role at gene therapy developer
March 22, 2022
FDA approves new epilepsy drug, handing Marinus a long-awaited victory
March 21, 2022
Biogen and its partner rework terms of Aduhelm deal amid slow sales
March 15, 2022
AbbVie keeps up dealmaking pace in neuroscience
March 11, 2022
After slower-than-expected review, Pfizer and Arena close buyout deal
March 10, 2022
Sanofi, with positive data in hand, to ask for approval of longer-lasting hemophilia therapy
March 9, 2022
Novartis turns to Voyager for nervous system gene therapies
March 8, 2022
Gilead says breast cancer drug succeeded in key study, but offers few details
March 7, 2022
Biogen, struggling to sell Alzheimer's drug, begins layoffs to save money
March 3, 2022
FDA rejects Gilead's closely watched HIV drug
March 1, 2022
Viatris sells off biosimilars business in $3.3B deal
Feb. 28, 2022
Biohaven stocks up on experimental drugs with new acquisition, licensing deal
Feb. 25, 2022
Lilly puts $700M into genetic medicine institute
Feb. 22, 2022
With drug approval, Agios hits first key milestone after major shakeup
Feb. 18, 2022
Yumanity cutting 60% of employees as it mulls possible sale
Feb. 17, 2022
Star Therapeutics emerges with plans to treat rare diseases through a solar system of drug companies
Feb. 16, 2022
Seagen shares sink as sales outlook of cancer drug disappoints
Feb. 10, 2022
Editas' executive shake-up continues
Feb. 8, 2022
More federal regulators investigating Biogen Alzheimer's drug
Feb. 4, 2022
Biogen's Alzheimer's drug sales remain slow as company warns of further cost cuts
Feb. 3, 2022
Pressure rises as Gilead awaits important study results for top cancer drug
Feb. 2, 2022
Madrigal adds to safety data for NASH drug
Jan. 31, 2022
Biogen, facing pressure on all sides, sells stake in biosimilars business
Jan. 28, 2022
Touting a new way to drug an all-important family of proteins, a startup launches with $100M
Jan. 27, 2022
Sierra Oncology records success in late-stage study of bone cancer drug
Jan. 25, 2022
Roche sees cause for optimism with failed Huntington's disease drug. Others aren't so sure.
Jan. 21, 2022
FDA approves AbbVie, Pfizer drugs for eczema, creating competition for Sanofi
Jan. 18, 2022
Medicare faces blowback over plan to limit coverage of Biogen's Alzheimer's drug
Jan. 14, 2022
5 questions facing biotech M&A in 2022
Jan. 12, 2022
Medicare proposes to limit coverage of Biogen Alzheimer's drug
Jan. 11, 2022
JPM22: Pfizer's big bet on mRNA, Biogen 'proven wrong' on Aduhelm price and the next cell therapies
Jan. 10, 2022
Lilly pours more money into genetic treatments for neurological diseases
Jan. 6, 2022
5 FDA approval decisions to watch in the first quarter
Jan. 5, 2022
Biogen brings in a successor to Spinraza
Jan. 4, 2022
Gilead, following Merck, hits its own safety setback in HIV
Dec. 22, 2021
GSK's long-acting HIV shot approved for preventive use
Dec. 21, 2021
After intense pushback, Biogen to cut price of Alzheimer's drug
Dec. 20, 2021
European regulators say no to Aduhelm, but Biogen is pushing back
Dec. 17, 2021
Biogen reserves four years for trial meant to confirm its Alzheimer's drug works
Dec. 16, 2021
Lilly ups revenue forecast amid windfall from COVID-19 drugs
Dec. 15, 2021
On the hunt for new ALS drugs, researchers see progress, and a long road ahead
Dec. 13, 2021
Fresh data show UniQure's hemophilia gene therapy appears to hold up
Dec. 9, 2021
A high-profile gene therapy biotech takes aim at Huntington's
Dec. 8, 2021
AbbVie's blockbuster weighed down by safety concerns for a similar Pfizer drug
Dec. 6, 2021
Sobi buyout breaks down
Dec. 3, 2021
GSK sets sights on brain diseases through Oxford partnership
Dec. 2, 2021
With safety a concern, Merck, Gilead pause study of HIV drugs
Nov. 24, 2021
GSK dives into NASH, RNA interference with Arrowhead deal
Nov. 23, 2021
Neurocrine stocks up on a biotech's psychiatric drugs
Nov. 22, 2021
A worrisome safety signal slows Merck's HIV ambitions
Nov. 19, 2021
Al Sandrock, Biogen's top scientist and Aduhelm defender, to retire in surprise exit
Nov. 16, 2021
Moderna founder unveils new drug company focused on a different kind of RNA
Nov. 9, 2021
Novartis to sell long-held stake in Roche for nearly $21B
Nov. 4, 2021
Cystic fibrosis group partners with Moderna founder to find better, potentially curative treatments
Nov. 3, 2021
Amylyx asks FDA to approve ALS drug, while also preparing late-stage study
Nov. 2, 2021
Despite strong quarter, some wonder how long Gilead can rely on coronavirus drug
Oct. 29, 2021
With approval plans underway, Lilly's next move is to test its Alzheimer's drug against Biogen's
Oct. 26, 2021
With Merck blocking its path, a small biotech reroutes, to the dismay of investors
Oct. 22, 2021
Biogen's Alzheimer's drug is struggling, and a turnaround might not be coming soon
Oct. 20, 2021
Sage, Biogen detail plans to get their newer depression drug approved
Oct. 19, 2021
Biogen's closely watched ALS drug comes up short in late-stage study
Oct. 18, 2021
Intellia looks to eye diseases in latest deal
Oct. 13, 2021
Takeda takes aim at a biotech's gene therapy work
Oct. 12, 2021
Armed with half a billion dollars, a startup aims to change how brain drugs are made
Oct. 7, 2021
5 FDA approval decisions to watch in the fourth quarter
Oct. 1, 2021
Acceleron provides biggest biopharma deal this year, with $11.5B sale to Merck
Sept. 30, 2021
Bluebird officially asks FDA to approve gene therapy for rare blood disorder
Sept. 22, 2021
Theravance to lay off 75% of employees alongside larger restructuring
Sept. 15, 2021
After talks with FDA, a biotech prepares to submit its closely watched ALS drug
Sept. 15, 2021
Biotech funder Lightstone raises another $375M for life sciences investing
Sept. 14, 2021
AbbVie bets big on a gene therapy for eye diseases
Sept. 13, 2021
Biogen offered a window into what's holding up Aduhelm. Investors didn't like what they saw.
Sept. 9, 2021
Venture capital pours more money into RNA medicines with the launch of Replicate
Sept. 8, 2021
With safety worries mounting, FDA limits who can take certain immune-regulating drugs
Sept. 1, 2021
Astellas again hits pause on gene therapy trial
Sept. 1, 2021
Galapagos CEO to retire, though successor yet to be announced
Aug. 31, 2021
Moderna founder's next big play in RNA raises $440M
Aug. 30, 2021
Lilly puts more money into protein degradation
Aug. 25, 2021
Vertex, looking to broaden its gene editing abilities, asks a young biotech for help
Aug. 24, 2021
J&J chief Alex Gorsky to step down early next year
Aug. 20, 2021
Private equity dives deeper into biotech with nearly $2B Bain fundraise
Aug. 17, 2021
Lilly's new eczema drug scores in late-stage studies
Aug. 16, 2021
Biotech’s M&A outlook is uncertain. Track the deals that are happening here.
Aug. 10, 2021
Bluebird to wind down business in Europe amid gene therapy struggles
Aug. 9, 2021
HHS watchdog to review FDA accelerated approval process after Aduhelm controversy
Aug. 4, 2021
After controversial approval, doctors are still debating how to use Biogen's Alzheimer's drug
Aug. 3, 2021
FDA rejects a biotech's kidney drug, but some analysts still see a 'sliver of hope'
July 30, 2021
Biogen, Ionis tout data from early study of RNA-based Alzheimer's drug
July 27, 2021
Denali drug for rare brain disease disappoints investors
July 26, 2021
Major health centers, insurers push back against Aduhelm
July 15, 2021
Biohaven CEO on migraine drug's fast launch, TikTok ads and battling big pharma
July 14, 2021
Bluebird resumes marketing gene therapy in Europe
July 9, 2021
Gene therapy for sickle cell disease: progress and competition
July 8, 2021
FDA knocks back diabetes prevention drug, crushing its maker's shares
July 6, 2021
GSK returns to brain drugs with major biotech deal
July 2, 2021
Pfizer's neuroscience spinout scores in schizophrenia
June 29, 2021
European regulators push 8 drugs toward approval, including controversial anemia pill
June 25, 2021
With Alzheimer's drugs in focus, Bristol Myers rejoins the hunt
June 24, 2021
FDA documents show how controversial Alzheimer's drug decision was reached
June 22, 2021
A year after getting UniQure's gene therapy, hemophilia patients are still doing better
June 22, 2021
Public Citizen calls for top FDA officials to resign following Alzheimer's drug approval
June 16, 2021
Biogen gene therapy deal has yet to bear fruit
June 15, 2021
Moderna founder raises another $2B to fuel new startups
June 14, 2021
Vertex stops work on second rare disease drug after study results disappoint
June 10, 2021
A first-of-its-kind Alzheimer's drug raises heavy questions around who will and won't get it
June 8, 2021
In historic move, FDA approves a closely watched and controversial Alzheimer's drug
June 7, 2021
Biotech venture capital still booming as venBio raises another $550M
June 3, 2021
Alkermes prepares for uncertain launch as FDA finally clears schizophrenia drug
June 1, 2021
A biotech backs off NASH after trial failure
May 24, 2021
Bluebird's next gene therapy gets backing from European regulator
May 21, 2021
In the midst of a 'strategic shift,' Voyager loses CEO and R&D head
May 20, 2021
FDA approval sets stage for a showdown between Alexion and Apellis
May 17, 2021
Third Rock launches biotech targeting 'notoriously difficult' DNA regulators
May 13, 2021
Biogen looks to build better gene therapies through latest deal
May 11, 2021
Moderna founder launches new biotech, looking to cure diseases through 'endless RNA'
May 10, 2021
Sage braces for make-or-break depression data
May 4, 2021
Wall Street fears Amgen's tough first quarter is just the start
April 28, 2021
Under pressure, Biogen will allow some patients early access to experimental ALS drug
April 27, 2021
Vertex moves pain drug into mid-stage testing
April 26, 2021
As review of its Alzheimer's drug wraps up, Biogen prepares for an uncertain launch
April 22, 2021
With money pouring into biotech, Versant raises another $950M
April 21, 2021
The next 2 months in biotech and pharma will be busy. Here's what to watch.
April 20, 2021
Vertex bets another $900M on CRISPR treatment for blood diseases
April 20, 2021
FDA faces backlash after seeking more data on an experimental ALS therapy
April 14, 2021
Gilead stops Veklury study, citing enrollment challenges, changing treatment
April 13, 2021
Provention Bio latest drugmaker flagged for 'deficiencies' in FDA approval application
April 9, 2021
Biogen adds a late-stage prospect to its growing biosimilar business
April 8, 2021
New data push a biotech's muscle disease drug closer to a key test
April 6, 2021
Acadia, with drug application rejected, calls out FDA for backtracking
April 5, 2021
FDA advisers reassert case against approval of Biogen's Alzheimer's drug
March 31, 2021
A biotech shelves its Huntington's drugs after trial failures
March 30, 2021
5 FDA approval decisions to watch in the second quarter
March 29, 2021
Pfizer and Lilly's pain drug hits setback in negative committee vote
March 26, 2021
Drugmakers flock to Vineti's fix for a cell, gene therapy problem
March 24, 2021
José Baselga, prominent cancer researcher, dies at 61
March 22, 2021
AbbVie's approval delay raises further concerns about JAK drugs
March 18, 2021
Global Blood takes on more sickle cell drugs through Sanofi deal
March 16, 2021
Gilead, Merck combine forces in HIV
March 15, 2021
Vertex begins human testing for diabetes cell therapy
March 10, 2021
Acadia shares plunge after unexpected FDA feedback
March 9, 2021
Merck gives an early peek at COVID-19 drug results
March 8, 2021
Galapagos reports long-awaited safety data for inflammation drug
March 4, 2021
Takeda takes full control of drug for rare epilepsies
March 3, 2021
A closely watched schizophrenia drug fails key test
March 2, 2021
Sarepta wins FDA approval of another drug for rare muscular dystrophy
Feb. 25, 2021
Merck to buy autoimmune drugmaker for $2B
Feb. 25, 2021
After FDA feedback, a biotech's ALS therapy faces murky path forward
Feb. 22, 2021
Lilly wagers almost $1B on Rigel's drugs for immune and nervous systems
Feb. 18, 2021
Gates Foundation backs Novartis' search for a sickle cell cure
Feb. 17, 2021
AbbVie exploring how CRISPR gene editing can improve cell therapies
Feb. 10, 2021
Lilly CFO steps down after investigation found 'inappropriate' behavior
Feb. 9, 2021
Biogen laser-focused on Alzheimer's drug as rest of business falters
Feb. 3, 2021
Vertex comes to a crossroads
Feb. 2, 2021
Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca
Feb. 1, 2021
FDA delays verdict for Biogen's closely watched Alzheimer's drug, raising investor optimism
Jan. 29, 2021
Safety finding weighs on Pfizer's inflammation drug, and could spell trouble for others
Jan. 27, 2021
FDA approves first-of-its-kind lupus drug
Jan. 25, 2021
Long-acting HIV drug secures FDA approval, giving GSK a competitive boost
Jan. 22, 2021
Biohaven adds to a long list of Alzheimer's drug failures
Jan. 19, 2021
Dana-Farber launches venture fund targeting incurable cancers
Jan. 15, 2021
5 trends in biotech dealmaking to watch in 2021
Jan. 13, 2021
Lilly rockets up on mixed Alzheimer's results
Jan. 11, 2021
Alnylam, with positive data in hand, prepares to submit 4th drug for approval
Jan. 7, 2021
Dewpoint forges another big pharma partnership — and a potential rivalry
Jan. 6, 2021
A new, well-connected biotech aims to fight cancer with viruses
Jan. 5, 2021
Amgen's asthma drug takes a hit, making for stiffer competition with Regeneron
Dec. 22, 2020
Cancer case puts UniQure's hemophilia gene therapy on hold, raising alarms
Dec. 21, 2020
Novartis acquires a small biotech and its trio of brain drugs
Dec. 17, 2020
Gilead hands back some rights to key drug from Galapagos deal
Dec. 16, 2020
Pharmacquired: What a surprise deal does for AstraZeneca and Alexion
Dec. 16, 2020
AstraZeneca to buy Alexion for $39B
Dec. 12, 2020
Lilly's coronavirus drug partner nails down one of biotech's largest IPOs
Dec. 11, 2020
Gilead inks a billion-dollar deal for a hepatitis drug
Dec. 10, 2020
Armed with big pharma cash, another startup takes aim at mysterious clusters of molecules
Dec. 9, 2020
UniQure offers a closer look at the leading hemophilia B gene therapy
Dec. 8, 2020
Lilly, UnitedHealth explore how to best use a COVID-19 antibody drug
Dec. 4, 2020
4 storylines to track at the year's biggest meeting on blood diseases
Dec. 3, 2020
J&J pushes further into eye gene therapy
Dec. 2, 2020
Biogen stocks up on Sage's brain drugs in $3B deal
Nov. 27, 2020
How Gilead finally spent its money
Nov. 24, 2020
Lilly dives into gene editing
Nov. 20, 2020
Stem cell therapy for ALS fails a large clinical trial
Nov. 17, 2020
Japanese drugmaker takes full control of a Roivant biotech
Nov. 13, 2020
Amgen's asthma drug delivers a needed win
Nov. 10, 2020
5 takeaways from the FDA's high-stakes meeting for Biogen's Alzheimer's drug
Nov. 9, 2020
FDA advisers vote against Biogen's Alzheimer's drug, leaving its future in doubt
Nov. 6, 2020
Biogen surges as FDA reviewers appear supportive of Alzheimer's drug approval
Nov. 4, 2020
The meeting that could change Alzheimer's treatment
Nov. 3, 2020
Regeneron pauses study of rare disease drug following patient deaths
Nov. 2, 2020
Novartis eyes its next move in gene therapy
Oct. 29, 2020
Bristol Myers taps machine-learning biotech for help finding ALS drugs
Oct. 28, 2020
Sarepta, continuing its gene therapy push, helps launch a startup
Oct. 22, 2020
Purdue, reaching $8B settlement with US, pleads guilty to charges over opioid sales
Oct. 21, 2020
Biogen is running out of safety nets
Oct. 21, 2020
Early signs of survival benefit raise optimism around a small biotech's ALS drug
Oct. 16, 2020
Vertex faces first notable setback as it pushes beyond cystic fibrosis
Oct. 14, 2020
Gossamer plummets as its lead drug fails 2 studies
Oct. 13, 2020
Pharmacquired: Splashy deals belie a shallow pool of heart drugs left to acquire
Oct. 8, 2020
With a sweetened offer, BridgeBio plans to reel in a subsidiary
Oct. 5, 2020
Pfizer pushes deeper into China with stake in cancer biotech
Sept. 30, 2020
Biogen's all-important Alzheimer's drug enters the review gauntlet
Sept. 29, 2020
After setback in the US, Galapagos' main drug finds success elsewhere
Sept. 28, 2020
GSK inhaler locks down a coveted approval in asthma
Sept. 10, 2020
Sanofi's hemophilia drug comes into focus as delays hit a key competitor
Sept. 10, 2020
Intra-Cellular roars back on success in bipolar depression
Sept. 9, 2020
Cancer drug approval puts Blueprint up against Lilly
Sept. 8, 2020
AbbVie wagers up to $2B on a Chinese biotech's cancer drug
Sept. 4, 2020
FDA scolds Mylan for 'repeated' manufacturing problems
Sept. 3, 2020
After a rare win, a biotech details long-awaited results for its ALS drug
Sept. 2, 2020
Gilead deal reignites optimism in a cancer biotech
Sept. 1, 2020
Ionis, changing its strategy, reels its spinoff back in
Aug. 31, 2020
With latest data, a gene therapy for a deadly brain disease inches closer to market
Aug. 29, 2020
BioMarin's hemophilia gene therapy could have warranted a record price tag, ICER finds
Aug. 28, 2020
New data lead Ovid, Takeda to push seizure drug into final testing
Aug. 25, 2020
Proteostasis bows out of cystic fibrosis drugmaking through Yumanity merger
Aug. 24, 2020
BioMarin's gene therapy rejection didn't shock everyone
Aug. 20, 2020
In major surprise, FDA rejects high-profile therapies from BioMarin, Gilead
Aug. 19, 2020
A cure for hemophilia seemed closer than ever. For many patients, it’s now further out of reach
Aug. 18, 2020
Bayer, contrasting pharma peers, builds up women's health business with $425M deal
Aug. 11, 2020
Seres finds the microbiome data it's been waiting for
Aug. 10, 2020
FDA agrees to review Biogen's Alzheimer's drug
Aug. 7, 2020
Biogen makes a billion-dollar bet on Parkinson's drugs
Aug. 6, 2020
FDA rejects a peanut allergy treatment, sinking a small biotech's shares
Aug. 4, 2020
Big pharma alliance recruits first patients for unusual COVID-19 study
Aug. 3, 2020
Vaccine sales driven down by pandemic's effects on doctor visits
July 31, 2020
Can Sanofi's top drug carry it through a pandemic?
July 29, 2020
Sandoz earmarks $175M to upgrade tech at European hub for antibiotics manufacturing
July 27, 2020
Gilead's second act in cell therapy gets its first approval
July 24, 2020
UK to spend almost $130M more on coronavirus vaccine manufacturing
July 23, 2020
Biogen points to COVID-19 for disappointing drug launch
July 22, 2020
At a pivotal moment, Biogen loses another top executive
July 22, 2020
Gilead adds to string of cancer drug deals with Tizona stake
July 21, 2020
GSK invests in mRNA vaccines through deal with CureVac
July 20, 2020
Sanofi, on the lookout for acquisitions, may have spotted a target
July 17, 2020
Blackstone caps off private equity's largest-ever life sciences fund
July 10, 2020
Big pharma, battling COVID-19, looks to 'buy time' on another health crisis: superbugs
July 9, 2020
In the hunt for ALS treatments, researchers find promise in silencing genes
July 8, 2020
Biogen submitted its Alzheimer's drug for approval. Now what?
July 8, 2020
Bellus shares plummet as cough drug fails Phase 2 test
July 6, 2020
Amgen prevails in high-stakes drug case against Novartis
July 1, 2020
Gilead pricing suggests it will make a business out of COVID-19 drug
June 30, 2020
Intercept's NASH drug faces its biggest delay yet
June 29, 2020
FDA rejects AbbVie's eye drug, citing safety concerns
June 26, 2020
Sanofi's fight for a better research reputation
June 23, 2020
Sarepta tries to fine-tune its gene therapy approach
June 22, 2020
In big year for microbiome drugs, a small biotech sets the bar
June 19, 2020
Sanofi's latest investment signals long-term focus on vaccines
June 16, 2020
Neurocrine bets $2B on Takeda's psychiatry drugs
June 16, 2020
Magenta's technology attracts another gene therapy developer
June 15, 2020
Agios, seeking a new strategy, touts positive data and marketing deal
June 12, 2020
Lundbeck to cut more than 100 jobs as it remodels R&D
June 9, 2020
Amid a pandemic, Atlas becomes latest venture firm to raise cash for drug startups
June 5, 2020
Pfizer business head details new $500M project for investing in public biotechs
June 3, 2020
Details lacking, but new remdesivir data point to a benefit for 'moderate' COVID-19 patients
June 1, 2020
Lilly wins first-ever FDA approval for drug that can spot Alzheimer's 'tau tangles'
May 29, 2020
Contaminated diabetes drugs raise red flag for FDA oversight
May 28, 2020
Venture capital found its footing in biotech. Then came the virus.
May 26, 2020
High expectations cast a shadow over Gilead and Galapagos' positive data
May 21, 2020
Little-known drug manufacturer gets big contract for COVID-19 response
May 19, 2020
Gilead licenses COVID-19 drug to 5 generics companies
May 13, 2020
GenFit delivers latest NASH drug failure
May 11, 2020
MyoKardia pops as heart drug passes most important test
May 11, 2020
After trial failure, Enanta narrows its focus to NASH
May 7, 2020
Novo's diabetes drug also appears to work in NASH
May 6, 2020
After 2 months of work, Alnylam has its top pick for a COVID-19 drug
May 4, 2020
Agios drops as COVID-19 takes a toll on drug studies
May 1, 2020
Vertex's drug launch hits new heights, but further growth could be harder to find
April 30, 2020
Merck starts to feel COVID-19's effects
April 28, 2020
Axsome, beating the odds, finds success treating Alzheimer's agitation
April 27, 2020
Launch for Neurocrine Parkinson's drug put on hold because of coronavirus
April 24, 2020
Biogen hammered with questions as Alzheimer's drug moves slower than expected
April 22, 2020
After 'superspreading' event, Biogen to build hub for COVID-19 patient data
April 16, 2020
Blackstone backs Alnylam with up to $2B investment
April 13, 2020
Takeda, CSL forge coronavirus alliance, forgoing their own drugs in the process
April 7, 2020
Alnylam and Dicerna are pals now, which could spell trouble for Arrowhead
April 6, 2020
Ultragenyx's gene therapy technology finds another interested party
April 1, 2020
A small NASH drugmaker finds positive data, but coronavirus makes for a 'tricky' path forward
March 31, 2020
J&J picks top coronavirus vaccine candidate; human tests to start in September
March 30, 2020
5 FDA approval decisions to watch in the 2nd quarter
March 30, 2020
Galapagos CEO talks next steps as coronavirus stalls the biotech's top drug
March 25, 2020
Novavax's positive flu data bring a stock bump and a spotlight on coronavirus vaccine
March 24, 2020
In hard-hit Seattle, coronavirus pushes biotechs to a new normal
March 19, 2020
Regeneron expects its antibody cocktail for coronavirus to enter human testing in early summer
March 17, 2020
Rubius scraps lead candidate as it exits rare disease drugmaking
March 12, 2020
Acceleron shelves drug after disappointing readout
March 10, 2020
Tracking biopharma's response to the new coronavirus
March 9, 2020
Takeda starts work on treatment for coronavirus illness
March 4, 2020
Gilead breaks M&A lull with $5B immuno-oncology deal
March 2, 2020
Biogen, Sangamo look to tackle Alzheimer's, Parkinson's through gene regulation
Feb. 27, 2020
Pharmacquired: Where are all the deals?
Feb. 27, 2020
Amid coronavirus fears, a generics giant pledges price stability
Feb. 26, 2020
Esperion adds more competition to cholesterol drug market
Feb. 21, 2020
BioMarin inches closer to a gene therapy first
Feb. 21, 2020
GenFit delays data readout, raising doubts about its place in NASH
Feb. 21, 2020
Teva's neuroscience drug falls short at the finish line
Feb. 20, 2020
Bluebird's gene therapy hits another delay, this time in the US
Feb. 19, 2020
Akebia locks down control over partner's new regulatory fast pass
Feb. 18, 2020
Cancer concerns knock Eisai's weight loss drug from market
Feb. 14, 2020
The cancer genes Wall Street is flooding with cash
Feb. 13, 2020
Bayer, looking to grow pharmaceutical sales, seeds new research center
Feb. 11, 2020
Biogen dips as Alzheimer's drugs from Lilly, Roche fail again
Feb. 10, 2020
Are Novartis and Regeneron seeing the same thing?
Feb. 7, 2020
Sanofi MS drug results set stage for extensive late-stage testing
Feb. 6, 2020
Biogen boosted as Mylan patent challenge fails
Feb. 5, 2020
Merck joins peers in spinning off lower growth drugs
Feb. 5, 2020
Bristol-Myers launches biotech targeting fibrosis, inflammation
Feb. 4, 2020
Catalent, expecting a boom in cell therapy, bids for Masthercell
Feb. 3, 2020
Vertex impresses with strong Trikafta launch
Jan. 30, 2020
German Merck continues manufacturing buildout with $275M investment
Jan. 30, 2020
With no Alzheimer's update, attention turns to Biogen's troubles
Jan. 30, 2020
Big pharma backed away from brain drugs. Is a return in sight?
Jan. 29, 2020
Acceleron soars on blood pressure data despite lengthy road to market
Jan. 28, 2020
Pfizer hits its biosimilar stride
Jan. 27, 2020
Ipsen pauses studies of drug for rare bone disease
Jan. 24, 2020
5 biopharmas to watch as the decade's last earnings kick off
Jan. 21, 2020
While expected, Intercept's approval delay adds to NASH uncertainty
Jan. 17, 2020
Orchard isn't for the picking, Biohaven's Allergan headache, and who's on Vascepa?
Jan. 16, 2020
Galapagos finds a new normal at biotech's biggest dealmaking event
Jan. 15, 2020
Neuroscience's decade, a biotech's 'crown jewel,' and Ionis gets selective
Jan. 15, 2020
Alexion's neuro bet, Rubius' trial troubles and biotech's gene therapy milestones
Jan. 14, 2020
BioMarin sets gene therapy sights beyond hemophilia
Jan. 13, 2020
Moderna, though early in development, prepares its vaccine for market
Jan. 9, 2020
Lilly looms over Blueprint as the biotech files targeted cancer drug
Jan. 8, 2020
GSK's plan to take over the HIV drug market hasn't worked out
Jan. 6, 2020
5 FDA approval decisions to watch in the 1st quarter
Jan. 2, 2020
Intra-Cellular approval keeps focus on FDA's neuroscience review process
Dec. 23, 2019
Biogen, Novartis go different ways on Ionis therapies
Dec. 19, 2019
Global Blood taps Syros for its next act in blood disorders
Dec. 18, 2019
Gilead's NASH ambitions buckle under the weight of ATLAS
Dec. 16, 2019
Biogen's Alzheimer's drug gets caught in Sarepta's spotlight
Dec. 13, 2019
Merck's ArQule buy showcases pharma appetite for targeted cancer drugs
Dec. 9, 2019
Biotech of the Year: Galapagos
Dec. 9, 2019
Readout of the Year: Aducanumab's surprise revival
Dec. 9, 2019
Biogen's Alzheimer's pitch yields few converts
Dec. 7, 2019
The clearest picture of Biogen's Alzheimer's drug is still fuzzy
Dec. 5, 2019
What to watch as Biogen presents its all-important Alzheimer's data
Dec. 4, 2019
Biogen scores a rare lupus win, lending support to its new immunology focus
Dec. 3, 2019
Before 2019 closes, the FDA has 3 key approval decisions to make
Nov. 27, 2019
2 NASH drugmakers have wildly different Mondays
Nov. 25, 2019
Novartis reshapes China R&D hub to reflect rapidly evolving market
Nov. 18, 2019
Roche wagers $1.4B that Promedior has its next big fibrosis drug
Nov. 15, 2019
Merck wants to know if taking out cellular trash can treat Alzheimer's
Nov. 13, 2019
Reata's kidney data gets a tepid response from investors
Nov. 12, 2019
CF Foundation puts half a billion dollars toward drugs for all patients
Oct. 30, 2019
What to make of Gilead's latest NASH deal
Oct. 28, 2019
Pharmacquired: Eylea could be in trouble, but that doesn't make Regeneron a buyer
Oct. 25, 2019
Vertex clears its biggest commercial hurdle: UK insurance coverage
Oct. 24, 2019
In major surprise, Biogen will ask FDA to approve Alzheimer's drug aducanumab
Oct. 22, 2019
Vertex wins speedy approval for cystic fibrosis triplet
Oct. 21, 2019
GSK hands 2 of its less profitable vaccines to Bavarian Nordic
Oct. 21, 2019
Alexion bids for a smaller version of itself, spurring concerns about the FTC
Oct. 16, 2019
Reata surprises with positive data in challenging rare disease
Oct. 15, 2019
Five Prime's restructuring claims more jobs
Oct. 11, 2019
UCB bets more on rare disease drugs with Ra Pharma acquisition
Oct. 10, 2019
Eylea casts a shadow over Novartis' latest approval
Oct. 8, 2019
After more than a year, Gilead finds new chief medical officer
Oct. 7, 2019
Gilead's follow-on PrEP drug gets broad label, but with a notable exclusion
Oct. 4, 2019
Gene therapy stocks have taken a beating. Their recovery may be slow
Oct. 3, 2019
Biogen's R&D head is out, following string of clinical setbacks
Oct. 1, 2019
Sobi finds another fit for its dealmaking strategy
Sept. 30, 2019
Pfizer's new JAK drug works, but class safety concerns linger
Sept. 27, 2019
Investors conclude there are probably better NASH drugs than Enanta's
Sept. 26, 2019
Alder's migraine drug attracted plenty of dealmakers. The company, not so much
Sept. 24, 2019
Cancer centers stretching to keep up with pharma's oncology interest
Sept. 23, 2019
Merck, Pfizer execs explain how they tap sites for cancer trials
Sept. 23, 2019
J&J finds competitive edge with latest Erleada approval
Sept. 18, 2019
Vertex hits a biomarker bump on road to new drug
Sept. 17, 2019
Opioid giant Purdue files for bankruptcy to pay for sweeping settlement
Sept. 16, 2019
Vertex makes headway in UK reimbursement
Sept. 12, 2019
Drug companies pay for exclusive access to UK genetic data
Sept. 11, 2019
Survey suggests Ionis is losing battle against Pfizer and Alnylam
Sept. 10, 2019
Celltrion taps Lonza to produce some of its Remicade biosimilar
Sept. 5, 2019
Pharmacquired: Vertex has an appetite for deals. Gene therapy is on the menu
Sept. 5, 2019
Skyrizi looks ready to soar after strong launch
Sept. 4, 2019
Catalent's legacy business outshined by acquisitions
Aug. 29, 2019
FDA issues safety warning for newer hepatitis C drugs following patient deaths
Aug. 28, 2019
Biopharma jobs boom in Massachusetts, though challenges still exist
Aug. 27, 2019
Pfizer injects $500M more into gene therapy manufacturing
Aug. 21, 2019
NHS coverage opens up Hemlibra to thousands more patients
Aug. 21, 2019
AstraZeneca diabetes drug posts more positive heart data
Aug. 20, 2019
Price, safety will test blockbuster billing for AbbVie's new arthritis drug
Aug. 16, 2019
Meet the protein responsible for nearly $100B in cancer drug deals
Aug. 16, 2019
Nonprofit under pressure to make new TB drug affordable
Aug. 15, 2019
Lilly bests J&J, with implications for AbbVie's new immunology star
Aug. 13, 2019
As Ebola outbreak rages, researchers find promise in Regeneron drug
Aug. 12, 2019
Gilead's Descovy set for PrEP approval, but not without data, access concerns
Aug. 8, 2019
Dupixent brings long-awaited profits to Sanofi, Regeneron partnership
Aug. 6, 2019
Regulators, Gilead at odds over HIV drug's use in women
Aug. 5, 2019
Clovis dives as investor pessimism reaches 'unprecedented levels'
Aug. 2, 2019
Vertex expects more, perhaps bigger M&A to come
Aug. 1, 2019
Teva, Endo among generics paying $70M in California pay-for-delay settlement
July 29, 2019
Novartis heart drug misses on potentially billion-dollar market
July 29, 2019
Neuroscience M&A is top of mind but a hard pill to swallow
July 29, 2019
European regulators back Bayer, GW drugs, but with caveats
July 26, 2019
Merck advancing 2-drug HIV hopeful
July 24, 2019
Biogen turns to eye, immune diseases to balance neuro gamble
July 23, 2019
5 questions going into this week's biopharma earnings
July 22, 2019
Gilead, Amgen, J&J most likely to buy Otezla, Wall Street predicts
July 18, 2019
Kite building out manufacturing as next cell therapy inches to market
July 16, 2019
GSK poses challenge to rival AstraZeneca with positive PARP data
July 15, 2019
ICER unconvinced peanut allergy drugs are better than just avoiding the food
July 11, 2019
New GSK data raises threat to Gilead's star HIV drug
July 10, 2019
UK testing Netflix-style payments to boost antibiotics development
July 9, 2019
BioMarin confirms timeline for hemophilia gene therapy, putting pressure on rivals
July 8, 2019
BioPharma Dive's 10 biggest stories of the spring
July 3, 2019
Once 'bodies for hire,' CROs are finding a new role as data specialists
June 28, 2019
Digital is bringing the change clinical trials need, DIA head says
June 28, 2019
Aiming for price transparency, Civica Rx hits snag with bundled payments
June 27, 2019
FDA officials see 'missed opportunity' with patient outcomes in clinical trials
June 26, 2019
Conatus hits all-time low as company explores strategic alternatives
June 25, 2019
Merck is on top. Investors worry there's only one way to go.
June 21, 2019
Catalent to buy Bristol-Myers plant to grow biologics, European business
June 19, 2019
Pharmacquired: Is $11B enough to secure Sanofi's spot in hemophilia?
June 19, 2019
Celgene dips out of deals ahead of mega-merger
June 17, 2019
Despite late-stage win, investors not sold on Global Blood sickle cell drug
June 14, 2019
Moody's: Amgen, Biogen, Gilead have 'high capacity' to do M&A
June 13, 2019
Sobi restructuring business around late-stage hematology, immunology drugs
June 12, 2019
NASH trial miss halves CymaBay's market value
June 11, 2019
NASH drugmaker stocks rebound after dip on FDA guidance
June 10, 2019
Sanofi finds new CEO in Novartis pharma head, Brandicourt to retire
June 7, 2019
Fresh off being bought, Apceth preps to supply Bluebird's gene therapy
June 6, 2019
Biotechs dive deeper into targeted cancer research, despite costs
June 5, 2019
MacroGenics dives as breast cancer drug shows small improvement
June 5, 2019
Pfizer, late on immunotherapy, charts faster course for targeted drugs
June 4, 2019
Seattle Genetics drug could provide new option for bladder cancer patients
June 3, 2019
AstraZeneca, Merck make case for PARP's place in pancreatic cancer
June 2, 2019
Mitsubishi pulls EU application for ALS drug, citing 'unwarranted' data request
May 31, 2019
PE firm nabs Vibalogics, banking on demand for complex viral products
May 30, 2019
Vertex chooses its cystic fibrosis future
May 30, 2019
Gilead C-suite shifts again with chief commercial officer appointment
May 29, 2019
Teva settles for $85M in Oklahoma opioid lawsuit
May 28, 2019
ICER sees current DMD therapies as too pricey, but notes data limitations
May 23, 2019
Lilly drug scores in Phase 2 Crohn's study
May 22, 2019
Merck puts $1B more into oncology, with kidney cancer a focus
May 21, 2019
UK charity sells Keytruda rights for $1.3B
May 20, 2019
The NASH dash runs into some early hurdles
May 17, 2019
No one knows the size of the NASH market
May 16, 2019
On the path to patients, NASH drugs may hit a payer roadblock
May 15, 2019
Will a big needle burst the NASH bubble?
May 14, 2019
Bayer pumping $150M more into biologics
May 13, 2019
Takeda offloads dry eye drug to Novartis for $3.4B
May 9, 2019
Gilead goes after a young biotech's data to break into kidney diseases
May 8, 2019
Catalyst dives as FDA approves rival's rare disease drug
May 7, 2019
Lundbeck builds out brain drug pipeline with $250M acquisition
May 6, 2019
Gilead's first move under new chief is to untether Kite
May 3, 2019
Amid outbreaks, Merck ramps up measles vaccine manufacturing
May 2, 2019
Pain, cancer, immunology drugs aren't bringing the relief Lilly needs
April 30, 2019
Elanco trying to fetch more out of specialty veterinary drugs
April 29, 2019
Praluent's lower list price isn't yielding better sales yet
April 26, 2019
Another late-stage miss knocks Gilead from its leading NASH position
April 25, 2019
Biogen points to M&A power as Wall Street presses for less risky programs
April 24, 2019
Lilly selling antibiotic rights, manufacturing plant in China
April 23, 2019
Lilly bets bigger on RNA drugs, with latest deal targeting immunology
April 22, 2019
Sandoz takes United Therapeutics to court for 'anticompetitive' behavior
April 18, 2019
Gilead taps into machine learning to find new NASH drugs
April 16, 2019
Catalent to buy Paragon for $1.2B as gene therapy demand grows
April 15, 2019
Wave delays key data readout for Huntington's therapy
April 11, 2019
Sanofi expands insulin savings program, but affordability still an issue
April 10, 2019
Time to test GSK's 2-drug HIV theory
April 9, 2019
United Therapeutics scraps drug after late-stage miss
April 8, 2019
No return for the Merrimack
April 5, 2019
Purdue searched for new advertising agency: report
April 3, 2019
AveXis buys its 4th US plant in preparation of Zolgensma launch
April 2, 2019
Novartis bets $1.6B on a biotech's anti-inflammatory drugs
April 1, 2019
Bluebird gene therapy on cusp of European market entry
March 29, 2019
Pfizer squeezes out positive data for fructose-fighting NASH drug
March 28, 2019
Purdue Pharma reaches $270M deal with Oklahoma to settle opioid claims
March 26, 2019
Bayer, J&J to settle Xarelto claims for $775M
March 26, 2019
Lilly reveals Humalog pricing details amid larger scrutiny over insulin costs
March 25, 2019
Pharmacquired: Biogen could use a big deal. Too bad it doesn't do those
March 22, 2019
Biogen halts Alzheimer's drug trials in major setback for biotech
March 21, 2019
Pfizer makes sure it won't get left out of the gene therapy deal boom
March 20, 2019
Sage's postpartum depression drug is approved. Now comes the hard part
March 19, 2019
Dermira shares double on positive eczema data
March 18, 2019
Amgen not done in quest to prove Repatha
March 15, 2019
Sandoz CEO to depart as Novartis doubles down on biosimilars
March 14, 2019
Dupixent label expansion opens door to thousands more patients
March 12, 2019
Axovant buoyed by early gene therapy data
March 11, 2019
AMAG pregnancy drug's future in doubt after key study miss
March 8, 2019
Roche outbid competing biopharma to secure Spark deal
March 7, 2019
Gilead scores key HIV data as Descovy proves non-inferior to Truvada
March 6, 2019
5 takeaways from Scott Gottlieb's surprising FDA departure
March 6, 2019
Biogen avoids heavy manufacturing lift in latest gene therapy deal
March 5, 2019
Biogen buys Nightstar in search of more eye gene therapies
March 4, 2019
AbbVie, Akcea benefit from latest CHMP recommendations
March 1, 2019
So far, so good for Alexion's Soliris follow-on
Feb. 28, 2019
Bristol-Myers hits a bump on road to Celgene takeover
Feb. 28, 2019
AstraZeneca's PARP drug succeeds in pancreatic cancer study
Feb. 27, 2019
Pharmacquired: What would a Clovis takeout look like?
Feb. 26, 2019
Roche acquires Spark in $4.8B gene therapy play
Feb. 25, 2019
Intercept stock drop reflects the high bar set for NASH drugs
Feb. 22, 2019
Allogene inks lease for new cell therapy manufacturing facility
Feb. 21, 2019
Merck takes a shot on Immune Design
Feb. 21, 2019
Pfizer tweaks Xeljanz trial after embolism safety signal
Feb. 20, 2019
CMS unveils CAR-T proposal, with emphasis on patient outcomes
Feb. 15, 2019
AstraZeneca retires Medimmune name amid sales turnaround
Feb. 14, 2019
Gilead's lead NASH drug not so STELLAR in first late-stage readout
Feb. 12, 2019
Eylea's PANORAMA data give fuller view of efficacy in label expansion bid
Feb. 11, 2019
Approving J&J's new depression drug would be an unusual move for the FDA
Feb. 8, 2019
J&J to disclose list prices in TV drug ads
Feb. 7, 2019
Tris Pharma's ibuprofen recall grows
Feb. 7, 2019
Mylan takes step toward knocking down key patent for Biogen's top seller
Feb. 7, 2019
Vertex fears its triplet will also face UK reimbursement battle
Feb. 6, 2019
Successful launch bolsters Libtayo's place as cornerstone therapy for Regeneron
Feb. 6, 2019
GSK bets billions more on oncology
Feb. 5, 2019
Pharma is shuffling around jobs, but a skills gap threatens the process
Feb. 4, 2019
Where are pharma's biggest layoffs happening?
Feb. 4, 2019
Does Merck need more than Keytruda?
Feb. 1, 2019
Novartis touts record year for manufacturing changes, but Kymriah still an overhang
Jan. 31, 2019
J&J's Erleada has big shoes to fill, and a tough competitor to boot
Jan. 31, 2019
Novartis finds stability in Cosentyx amid company shake-ups
Jan. 30, 2019
Biogen leaves analysts guessing on aducanumab
Jan. 29, 2019
Alexion's follow-on to Soliris succeeds in late-stage trial
Jan. 28, 2019
Wall Street can't look past AbbVie's Humira problem
Jan. 25, 2019
Senate Dems again targeting tax deductions for DTC drug ads
Jan. 23, 2019
Amid controversies, J&J voted most admired pharma
Jan. 23, 2019
A flashy 2019 start to pharma M&A, but will it last?
Jan. 22, 2019
Lilly suspends Lartruvo promotion after Phase 3 failure
Jan. 18, 2019
Boehringer building out biologics manufacturing in China
Jan. 17, 2019
Lilly rushed its Loxo deal to have a big reveal at JPM
Jan. 17, 2019
Aptinyx stung by pain drug's mid-stage miss
Jan. 16, 2019
At JPM, the NASH flood gates start to crack
Jan. 11, 2019
The winners and losers from JPM 2019
Jan. 11, 2019
J&J raises prices as Dems introduce bills aimed at lowering drug costs
Jan. 11, 2019
A biotech's M&A invitation and Editas' next CRISPR step
Jan. 10, 2019
Spark looks at scale, manufacturing as gene therapy matures
Jan. 10, 2019
FDA warns it won't be long before user fee funding runs dry
Jan. 9, 2019
Pain, depression and antipsychotic drugs drum up enthusiasm
Jan. 8, 2019
Sage soars on success of postpartum depression drug
Jan. 8, 2019
Pharmas spending too much on buybacks, not enough on big deals: report
Jan. 7, 2019
How Bristol-Myers' big buy could spur ripples for pharma M&A
Jan. 4, 2019
Seeking edge in oncology, Bristol-Myers bets big on blood cancer, cell therapies
Jan. 3, 2019
Eyeing NASH, Gilead wagers $1.5B on preclinical fibrosis drugs
Dec. 19, 2018
Vertex chalks up another win for pain drug
Dec. 18, 2018
Clovis dips as Tesaro reveals more details of its acquisition
Dec. 17, 2018
Merck shelling out $3.7B on digital solutions for animal health
Dec. 14, 2018
Biogen backs away from AGTC after gene therapy failure
Dec. 13, 2018
Lilly bets on AC Immune's tech to target Alzheimer's
Dec. 12, 2018
Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment
Dec. 11, 2018
Conatus unsuccessful in spinning NASH failure
Dec. 6, 2018
3 questions leaving ASH
Dec. 5, 2018
Hospital docs weigh in on CAR-T reimbursement: 'It's very complicated'
Dec. 5, 2018
At ASH, bispecific cancer therapies make a mark
Dec. 5, 2018
ASH18: Legend's CAR-T brought back to reality
Dec. 3, 2018
Biotech of the Year: Spark Therapeutics
Dec. 3, 2018
Deal of the Year: Takeda buys Shire
Dec. 3, 2018
ASH18: Bluebird's follow-on CAR-T finds initial success, but durability will be key test
Dec. 2, 2018
Changing markets: A look at rheumatoid arthritis
Nov. 30, 2018
M&A trends in 2019: Will the biotech bubble burst?
Nov. 30, 2018
Roche joins NASH dash with Jecure buy
Nov. 28, 2018
Vertex's first CF triplet shows early success in late-stage trials
Nov. 27, 2018
5 rheumatologists discuss the evolving landscape of RA treatment
Nov. 26, 2018
Drug costs pushed one-third of Americans to skip a prescription in the past year: GoodRx
Nov. 26, 2018
ASH data helps cement Darzalex's place in multiple myeloma standard of care
Nov. 21, 2018
Novartis confident in Gilenya despite FDA call out
Nov. 21, 2018
Sobi's late-breaking ASH data also spurs an approval
Nov. 20, 2018
Aimmune's peanut allergy drug draws mixed reactions
Nov. 19, 2018
MYSTIC deals another blow to AstraZeneca as Imfinzi misses on OS
Nov. 16, 2018
3 hemophilia patients lift uniQure's value more than $450M
Nov. 15, 2018
7 drugs that raised eyebrows in Q3
Nov. 15, 2018
Pfizer launches biosimilar version of Amgen's Epogen
Nov. 14, 2018
Sobi snags rights to AstraZeneca drugs in another immunology play
Nov. 13, 2018
AstraZeneca calls victory in CV study, but will payers feel the same?
Nov. 12, 2018
Gilead's search for the next great liver drug won't end with its FXR agonist
Nov. 9, 2018
AmerisourceBergen's compounding site still on ice despite beefed-up oversight
Nov. 8, 2018
PARP makers search for a way to break through
Nov. 8, 2018
Earnings reveal pharma's mixed feelings on Trump drug pricing proposal
Nov. 7, 2018
Despite Trulicity success, Lilly can't escape diabetes concerns
Nov. 6, 2018
Lilly strengthens Trulicity's leading position with REWIND results
Nov. 5, 2018
Red pill or blue? It could be a billion-dollar decision
Oct. 29, 2018
Endocyte deal showcases Novartis' complex manufacturing juggling act
Oct. 25, 2018
Biogen dips as BAN2401 data bring more questions than answers
Oct. 25, 2018
Amgen cuts US Repatha price 60% amid market pressure
Oct. 24, 2018
DTC's big issues: Trump, cancer drugs and the First Amendment
Oct. 24, 2018
Cryoport, in pursuit of smoother cell therapy logistics, opens new facility
Oct. 24, 2018
Biogen talks threats to Spinraza, but mum on BAN2401
Oct. 23, 2018
Lynparza hits a 'home run,' putting pressure on other PARP inhibitors
Oct. 22, 2018
FDA unconvinced by Novartis pitch for canakinumab
Oct. 19, 2018
Fresh data expands Pfizer's options for treating first-line kidney cancer
Oct. 18, 2018
Minnesota takes aim at Sanofi, Novo, Lilly for insulin prices
Oct. 17, 2018
Amgen, Lilly migraine drugs make it onto Express Scripts' preferred list
Oct. 17, 2018
J&J sees 'evolution in pricing, not a revolution' in 2019
Oct. 16, 2018
7 drugmakers to watch on Q3 earnings
Oct. 15, 2018
With latest deal, AbbVie keeps another Humira biosimilar at bay
Oct. 11, 2018
Regulators wary of how McKesson handles illegitimate drugs
Oct. 11, 2018
FDA clears Vertex, CRISPR to test gene-editing therapy in sickle cell patients
Oct. 10, 2018
Roche, Ionis focusing on eye disease through new deal
Oct. 10, 2018
Perrigo appoints new CEO, reshuffling leadership for 3rd time since 2016
Oct. 9, 2018
Approval puts Bausch step closer to dermatology turnaround
Oct. 8, 2018
Roche looks to wider market for Hemlibra with key approval
Oct. 4, 2018
J&J bets billions on RNA interference
Oct. 4, 2018
Hemophilia pressures have Bayer laying off 227 at California plant
Oct. 3, 2018
Paratek eyes 800 key hospital accounts for new antibiotic's rollout
Oct. 3, 2018
Aduro loses valuable partner as J&J exits licensing deals
Oct. 2, 2018
Akorn falls after judge rules Fresenius can exit takeover
Oct. 1, 2018
What you need to know about continuous manufacturing
Oct. 1, 2018
In a September full of pharma layoffs, Novo adds 250 more
Sept. 28, 2018
Novartis taps Cellular Biomedicines to supply Kymriah in China
Sept. 27, 2018
GW Pharma clears last big hurdle for cannabis-based Epidiolex with DEA rescheduling
Sept. 27, 2018
Pharma advertising in 2018: TV, midterms and specialty drugs
Sept. 26, 2018
Aldeyra has positive dry eye data — for now
Sept. 26, 2018
Takeda's dream of a first-line ALK inhibitor supported by late-stage data
Sept. 25, 2018
Gilead creates subsidiary to sell generic versions of hep C blockbusters
Sept. 24, 2018
J&J still has much to explore with continuous manufacturing
Sept. 24, 2018
For CDMOs, continuous manufacturing isn't an 'if,' but a 'how'
Sept. 24, 2018
Sarepta clears up clinical hold for gene therapy
Sept. 24, 2018
Sarepta strikes out again with European regulators
Sept. 21, 2018
Phase 3 win underscores that Astellas is more than Xtandi
Sept. 20, 2018
Novo's reorganizing claims more jobs, with R&D set to lose 400
Sept. 18, 2018
More data bolster AstraZeneca's 3-in-1 inhaler as other assets face setbacks
Sept. 17, 2018
Inbrija delay poses question: How far can Acorda fall?
Sept. 13, 2018
FINCH-2 data bodes well for Gilead, Galapagos JAK inhibitor
Sept. 11, 2018
Merck's pneumonia antibiotic stacks up in pivotal study
Sept. 11, 2018
As EpiPen struggles, Walgreens, Kaleo ink Auvi-Q partnership
Sept. 7, 2018
Akcea to reduce workforce 10% following Waylivra rejection
Sept. 6, 2018
Health systems roll out generic manufacturing company to meet hospital needs
Sept. 6, 2018
Gilead, Galapagos build case for JAK inhibitor with Phase 2 win
Sept. 6, 2018
Generics group says branded drugmakers blocking $13B in annual savings
Sept. 5, 2018
With 12 more patients dosed, Bluebird reinforces strong profile for Lenti-D
Sept. 5, 2018
BioPharma Dive's 10 hottest stories of the summer
Sept. 4, 2018
Merck's virology business needs a boost. It may not get that from 2 new HIV drugs
Aug. 31, 2018
What you need to know about the evolving regulatory landscape
Aug. 31, 2018
Catalent's growth blemished by weaker Softgel performance
Aug. 30, 2018
Pfizer shutters DMD program following failed study
Aug. 30, 2018
Despite new approval, Bayer continues to face hemophilia headwinds
Aug. 30, 2018
In a summer of C-suite departures, a week of commercial hires
Aug. 29, 2018
Waylivra rejection raises questions about Ionis, Akcea ability to close
Aug. 28, 2018
FDA ups the ante for copycats, antibiotics, orphan drugs. But is it working?
Aug. 27, 2018
Novartis, Gilead CAR-T therapies approved in Europe, putting spotlight on global manufacturing
Aug. 27, 2018
Approval in hand, Shire's next step is to deliver on high hopes for lanadelumab
Aug. 24, 2018
CSL's Seqirus expects to double flu vaccine production at NC plant
Aug. 23, 2018
Allergan may not lose much from latest FDA rejection
Aug. 22, 2018
EpiPen class action lawsuit against Mylan, Pfizer to continue, judge rules
Aug. 21, 2018
In pursuit of new insulins, Novo may drop more than $800M on Ziylo
Aug. 17, 2018
Opdivo gets speedy approval in 3rd-line small cell lung cancer
Aug. 17, 2018
After a hiring blitz, where is Mustang's CAR-T manufacturing headed?
Aug. 16, 2018
Pfizer puts up $425M in flu vaccines deal
Aug. 16, 2018
FDA seeks go-ahead to study risk info in DTC print ads
Aug. 15, 2018
J&J, ViiV tout positive data for two-drug HIV therapy
Aug. 15, 2018
Biogen's Spinraza gets an early no-go from NICE
Aug. 14, 2018
Regeneron quickly clears up 12-week Eylea CRL
Aug. 13, 2018
Manufacturing problems leave Jazz with 'extremely limited' Erwinaze supply
Aug. 9, 2018
FDA adcom support puts Paratek's antibiotic closer to approval
Aug. 9, 2018
Regeneron eyes DTC for its top-seller
Aug. 8, 2018
Regenxbio dips as gene therapy platform yields mixed results
Aug. 8, 2018
Teva confident migraine drug will launch this year despite new manufacturing woes
Aug. 7, 2018
Pain Therapeutics reorganizing as abuse-deterrent opioid rejected again
Aug. 6, 2018
Allergan sues Pfizer over legal fees tied to opioid marketing
Aug. 3, 2018
Celtaxsys CF drug misses mark on lung function
Aug. 2, 2018
With diabetes competitive as ever, Novo launches Ozempic DTC campaign
Aug. 1, 2018
Otsuka's 'next-gen' cancer drug flunks its first Phase 3 study
July 31, 2018
Daiichi acquires another ADC drug through Glycotope licensing deal
July 30, 2018
Merck, Bristol top earnings, but lung cancer rivalry remains the focus
July 27, 2018
Celgene bets on fantastic 5 to save portfolio
July 26, 2018
Rice-sized form of Roche's Lucentis heads for advanced testing
July 25, 2018
ResTORbio rockets up on questionable data
July 25, 2018
Biogen wants you to know it's more than BAN2401
July 24, 2018
Payers, doctors weigh AI's disruptive prescribing potential
July 23, 2018
Agios gets to prove its marketing abilities with new approval
July 23, 2018
Roche bets over $1B on tech that lets patients swallow antisense drugs
July 20, 2018
7 companies to watch during Q2 earnings
July 19, 2018
Allergan's eye drug stacks up against Lucentis, but wider market still iffy
July 19, 2018
AbbVie goes 3-0 in delaying Humira rivals
July 18, 2018
Where does J&J's new drug fit in the crowded HIV market?
July 18, 2018
J&J: Growth not dependent on Zytiga
July 17, 2018
5 drugs to watch as biotechs report Q2
July 16, 2018
Advaxis clinical hold lifted, but stock not so much
July 13, 2018
New epilepsy data sets Zogenix up for showdown with GW
July 12, 2018
Dova downgraded as high price tag threatens to slow new drug's pickup
July 11, 2018
Otsuka drops $430M to beef up antibody drug development
July 11, 2018
Celgene's blood drug scores again in Phase 3
July 10, 2018
Axovant parades new preclinical therapy, much to investor delight
July 9, 2018
DIA18: CRISPR, AI, blockchain and the future of drug development
June 28, 2018
DIA18: How much are PRVs even worth?
June 27, 2018
DIA18: Value-based contracts pose more questions than answers
June 26, 2018
What the pharma industry needs to know about vaccines
June 25, 2018
Why be a vaccine company?
June 25, 2018
Mustang opens CAR-T manufacturing plant, with focus on lead candidates
June 24, 2018
Boehringer invests $268M to further build out biologics
June 22, 2018
Incyte preps Jakafi expansion into graft-versus-host disease
June 21, 2018
3 patients add $2.5B to Sarepta's value
June 19, 2018
How badly does Alexion want its Soliris follow-on? Enough to use a rare fast pass
June 19, 2018
ObsEva's endometriosis win puts it back in investors' good graces
June 18, 2018
GSK touts two-drug HIV therapy, intends to file this year
June 14, 2018
Big pharma shows no signs of 'massive' drug price cuts
June 13, 2018
Eisai looking past amyloid, tau with new drug discovery center
June 13, 2018
Gene-editing biotechs drop as cancer concerns weigh on CRISPR
June 11, 2018
Vical abandons herpes vaccine after mid-stage miss
June 11, 2018
Novo dips on job cuts report
June 8, 2018
First Neulasta biosimilar headed to US market
June 6, 2018
ASCO18: Who were the big winners and losers?
June 6, 2018
ASCO18: Jounce plummets further on weak efficacy data
June 4, 2018
ASCO18: AbbVie blood cancer combo off to a strong start in Phase 2
June 3, 2018
ASCO18: So far, so good for Loxo's gene-focused cancer therapy
June 2, 2018
ASCO18: Positive readout marks step forward for Bluebird's CAR-T
June 1, 2018
ASCO18: Tecentriq scores again in lung cancer, but Keytruda looms in background
June 1, 2018
Vertex, CRISPR gene-editing therapy hit with clinical hold
May 31, 2018
Half of orphan drug sales to come from cancer, Evaluate finds
May 30, 2018
From the ashes, Axovant proves its recruiting skills are still top-notch
May 29, 2018
BioMarin cleared to bring new PKU drug to market
May 25, 2018
Recro plummets on CRL
May 24, 2018
Senators call for list prices in DTC ads
May 23, 2018
Teva says CGRP drug could gain approval by mid-September
May 23, 2018
J&J, Pfizer, Merck again lead pharma in Fortune 500
May 22, 2018
NASH drug pipeline headed toward uncertain market
May 21, 2018
Hemlibra's latest HAVEN results impress
May 21, 2018
Amgen, Novartis' closely watched migraine drug approved
May 18, 2018
FDA clears new tool in fight against opioid epidemic
May 17, 2018
Oncology boom spurs DTC advertising, and with it controversy
May 16, 2018
Merck, Eiger expand drug licensing deal to include rare disease indication
May 16, 2018
Lilly's CGRP drug succeeds in 'worst kind of migraine'
May 15, 2018
Lilly drops $110M to bring cancer compound back in house
May 14, 2018
Adcomm support removes one hurdle for Ionis, Akcea drug, but many remain
May 11, 2018
IPR protocol would change under new PTO proposal
May 10, 2018
Lipocine's testosterone drug rejected again
May 9, 2018
Outlook for Ionis, Akcea drug marred by safety concerns
May 8, 2018
ICER: Vertex's CF drugs too expensive
May 7, 2018
Celgene's timeline for refiling ozanimod gets mixed reviews
May 4, 2018
Despite stock slump, Regeneron remains as confident as ever
May 3, 2018
New approval sets up CAR-T showdown for Gilead, Novartis
May 2, 2018
Esperion tumbles as patient deaths weigh on cholesterol drug
May 2, 2018
Q1 earnings preview: Novo, Celgene still to come
May 1, 2018
Spark sells regulatory fast pass to Jazz for $110M
April 30, 2018
Allergan defends ubrogepant's marketability
April 27, 2018
Dupixent stumbles as Sanofi muddles through tough times
April 27, 2018
A metabolite will make or break Celgene's ozanimod
April 26, 2018
Shire, tight-lipped on Takeda, focuses on portfolio's potential
April 26, 2018
Supreme Court upholds constitutionality of IPR
April 25, 2018
The pharma supply chain: What you need to know
April 24, 2018
Lilly's JAK woes set the stage for AbbVie, Gilead to jump ahead
April 24, 2018
Immunotherapies, biosimilars to dominate next week of earnings
April 24, 2018
Lilly's baricitinib wins FDA panel nod, but still dogged by safety issues
April 23, 2018
CAR-T ups challenges in pharma supply chain
April 23, 2018
Out-of-pocket drug costs still murky, report underscores
April 20, 2018
J&J reshaping its supply chain around therapies of the future
April 19, 2018
P&G absorbs German Merck's consumer business for $4B
April 19, 2018
In win for generics makers, court knocks back Maryland price gouging law
April 18, 2018
ImmuPharma dives on late-stage lupus failure
April 18, 2018
Shire's oncology exit weighs on potential Takeda bid
April 16, 2018
Hanmi scraps lung cancer drug due to AstraZeneca rival, reports say
April 13, 2018
Q1 kicks off with J&J, Novartis, Glaxo results
April 13, 2018
Maker of Pfizer med warned for continued testing issues
April 12, 2018
PCSK9s appear to be meeting less payer resistance
April 12, 2018
Lawmaker questions HHS drug pricing appointee for industry ties
April 11, 2018
Alexion broadens pipeline with $855M Wilson Therapeutics buy
April 11, 2018
Latest Phase 3 failure underscores Alzheimer's indomitable nature
April 10, 2018
Keytruda shows OS benefit across broader range of lung cancer patients
April 9, 2018
Clovis closes in on rival PARP drugs with latest approval
April 6, 2018
Medicare to pay hundreds of thousands for CAR-T therapies
April 6, 2018
AGC in new expansion as biologics production heats up
April 5, 2018
Novo charts course for sickle cell amid headwinds in hemophilia
April 5, 2018
NICE's first impression of Dupixent: It's not cost-effective
April 4, 2018
Lilly's next diabetes play would have patients implanted with engineered stem cells
April 4, 2018
Celgene's COO departs amid immunology setbacks
April 3, 2018
PhRMA argues early notice of price hikes won't benefit patients
April 2, 2018
Teva's 'skinny label' generic didn't cause infringement of GSK's patent, judge finds
March 29, 2018
Novartis sues Regeneron over manufacturing methods
March 28, 2018
Teva launches generic version of Shire's top-selling internal medicine
March 28, 2018
Takeda eyes Shire takeover
March 28, 2018
AnaptysBio's new allergy data has investors scratching their heads
March 27, 2018
Abuse deterrents still finding their niche in the pain space
March 26, 2018
Ablynx's anti-inflammation drug fails in lupus
March 26, 2018
What's more prescribed than opioids? Weirdly, a thyroid drug
March 23, 2018
Thermo Fisher to grow European footprint with new supply chain site
March 22, 2018
Sun Pharma breaks into biologics with Ilumya
March 22, 2018
FDA to study how drug promotion affects doctors' decisions
March 21, 2018
New FDA transparency push begins with J&J's Erleada
March 20, 2018
Drug spending growth to come solely from specialty meds, report says
March 13, 2018
GSK dodges another Advair copy as FDA reaffirms Hikma rejection
March 12, 2018
CytomX loses out on $264M as Pfizer exits deal
March 9, 2018
Parexel finds new CEO in INC Research vet
March 8, 2018
Merck KGaA's BTK drug hits in Phase 2 MS study
March 8, 2018
For Cosentyx, Taltz, Siliq: A marketing race to differentiate
March 7, 2018
Despite positive data, Esperion still has high hurdle to clear
March 7, 2018
23andMe's DTC cancer test tentatively OK'd by FDA
March 7, 2018
Gilead builds case for switching to its new HIV triplet
March 6, 2018
Positive data pushes G1 to speed up development of its CDK inhibitor
March 5, 2018
Verona lifted as main asset shows promise in CF
March 2, 2018
Kodak touts study to lure pharma manufacturing
March 1, 2018
Portola investors are sick of AndexXa delays
March 1, 2018
Collegium warned for opioid drug marketing
Feb. 28, 2018
Hemlibra headed for Europe, eyes wider market
Feb. 27, 2018
Akorn tanks as puzzling probe threatens Fresenius deal
Feb. 27, 2018
Drug compounding oversight rises, but spotty: Pew
Feb. 26, 2018
The (still somewhat mysterious) science behind the microbiome
Feb. 26, 2018
Avonex's freefall still likely amid patent case loss
Feb. 26, 2018
Bristol losing its I/O talent to the likes of Pfizer, report finds
Feb. 23, 2018
Avid tapped to produce Enzyvant's rare disease candidate
Feb. 22, 2018
CDER in warning letter frenzy as pharma struggles with quality control
Feb. 21, 2018
Gilead wins reprieve in Merck's $2.5B patent lawsuit
Feb. 21, 2018
Merck buys virus maker to flesh out I/O pipeline
Feb. 21, 2018
AbbVie, Voyager set sights on 'one-time' Alzheimer's treatment
Feb. 20, 2018
Apricus plummets after ED drug rejection
Feb. 16, 2018
Bayer plant flagged by FDA for poor GMP practices
Feb. 15, 2018
Bioverativ taps new manufacturer as it steps out of Biogen's shadow
Feb. 15, 2018
Fresh data sets up showdown for Lilly's Taltz vs Cosentyx
Feb. 14, 2018
Shire's pushing its growth potential, but investors aren't sold
Feb. 14, 2018
New approval helps Vertex's 'cleanest growth story in biotech'
Feb. 13, 2018
Despite trial win, Roche's new eye drug can't escape Eylea's shadow
Feb. 12, 2018
SeaGen, Pieris ink deal for bispecific I/O drugs
Feb. 9, 2018
Isotope manufacturing headed back to US following new FDA approval
Feb. 8, 2018
Gilead HIV triplet wins approval, prompts GSK-backed patent lawsuit
Feb. 8, 2018
Pharma wades into the world of virtual reality marketing
Feb. 7, 2018
Biopharma in charts: Key takeaways from Q4 earnings
Feb. 5, 2018
Pfizer's manufacturing fix clears path for Momenta's Copaxone generic
Feb. 1, 2018
Vertex looks to own CF market before shifting focus
Jan. 31, 2018
Boehringer strikes Jardiance outcomes deal with Prime PBM
Jan. 31, 2018
Patient death, clinical hold sink Bellicum shares
Jan. 31, 2018
Sunovion Parkinson's drug scores in Phase 3
Jan. 30, 2018
When real-world evidence becomes a real headache
Jan. 29, 2018
Bioverativ investors slapped with insider trading lawsuit
Jan. 29, 2018
New COPD data aid AstraZeneca in uphill battle with GSK
Jan. 26, 2018
Pfizer's EpiPen woes creep into Canada
Jan. 25, 2018
Celgene's task: Turn its shiny new toys into growth drivers
Jan. 25, 2018
NYC seeks $500M in suit aimed at opioid manufacturers
Jan. 24, 2018
J&J signals new tax laws won't change its M&A strategy
Jan. 23, 2018
Idera, BioCryst to merge, fortifying their position in rare disease
Jan. 22, 2018
FDA skewers Chinese API maker for lax quality control
Jan. 18, 2018
Report: Small deals aren't the answer to big pharma's woes
Jan. 18, 2018
Shire's latest approval won't save it from Hemlibra
Jan. 17, 2018
AveXis builds out SMA program with new studies
Jan. 17, 2018
Novartis goes 2-0 against J&J in psoriasis
Jan. 16, 2018
AstraZeneca's PARP inhibitor gains market edge with breast cancer approval
Jan. 12, 2018
JPM18: Teva cutting up to 25 manufacturing sites within 2 years
Jan. 11, 2018
JPM18: Novavax investors cheer RSV vaccine update, then pull back
Jan. 11, 2018
Drug charity group bites back at HHS
Jan. 10, 2018
FDA slaps down Amneal bid to stop Forteo generics
Jan. 10, 2018
Teva, Alder ink migraine deal to avoid legal headache
Jan. 9, 2018
JPM18: Shire holds onto neuroscience unit, for now
Jan. 8, 2018
Novo Nordisk puts $3B on the table for Ablynx
Jan. 8, 2018
CNS drugs take center stage: BioPharma's 2018 predictions
Jan. 8, 2018
Taxes, tech and China to fuel pharma M&A in 2018, says EY
Jan. 7, 2018
With TiGenix buy and Denali deal, Takeda shows its hand
Jan. 5, 2018
Fresnius Kabi's investigations aren't up to snuff, says FDA
Jan. 4, 2018
Pfizer targets harmful proteins in $830M deal
Jan. 4, 2018
Big drugmakers ring in new year with price hikes
Jan. 3, 2018
Galapagos' progress won't rattle CF markets, analysts say
Jan. 3, 2018
AstraZeneca sells US rights to 4 non-core drugs
Jan. 2, 2018
Roche drops $1.7B for Ignyta and its lung cancer drug
Dec. 22, 2017
Biopharma trends to watch in 2018
Dec. 22, 2017
Fujifilm invests in gene therapy startup
Dec. 21, 2017
MilliporeSigma tapped by bluebird for manufacturing
Dec. 21, 2017
Biogen's Alzheimer's drug fails, putting focus all on aducanumab
Dec. 21, 2017
Biogen, Ionis looking for new SMA drugs following Spinraza's success
Dec. 20, 2017
Spending on prescription drugs has almost doubled since the '90s, report finds
Dec. 19, 2017
Shire's new Elaprase formulation fails late-stage trial
Dec. 19, 2017
Biotech IPOs show no signs of slowing down in 2018
Dec. 18, 2017
Shire looks to stall Hemlibra impact with court injunction
Dec. 18, 2017
Alnylam, Sanofi given the all-clear to resume fitusiran trials
Dec. 15, 2017
Abzena tapped for preclinical ADC development
Dec. 14, 2017
Teva to eliminate 14,000 positions in sweeping company overhaul
Dec. 14, 2017
Vertex licenses its first drug from CRISPR collaboration
Dec. 13, 2017
After a decade of work, Otsuka and GW part ways on Sativex
Dec. 13, 2017
Sanofi's Humalog follow-on gets FDA nod
Dec. 12, 2017
Pfizer's PARP inhibitor showcases efficacy in late-stage trial
Dec. 8, 2017
FDA lays groundwork for regulating 3D-printed drugs
Dec. 7, 2017
Lilly's Taltz gains new indication, improving position versus Cosentyx
Dec. 6, 2017
J&J, Lilly, Merck have best management in pharma, says report
Dec. 6, 2017
J&J, Sanofi ranked best for clinical trial transparency
Dec. 5, 2017
J&J jumps in on Actelion spinout's hypertension drug
Dec. 4, 2017
Biotech of the Year: Vertex Pharmaceuticals
Dec. 4, 2017
Disruption of the Year: Long-Acting Hemophilia Drugs
Dec. 4, 2017
The BioPharma Dive Awards for 2017
Dec. 4, 2017
Cali to Massachusetts: We're the better biotech hub
Dec. 1, 2017
Merck unveils big plans for new UK HQ
Nov. 30, 2017
Bayer decides it's time to stick research and development together
Nov. 30, 2017
FDA's generics goals may spell trouble for branded drug-device combos
Nov. 29, 2017
Medicines Co. sells infectious disease unit to put more money into PCSK9 drug
Nov. 29, 2017
AstraZeneca outlicenses Brilinta reversal agent
Nov. 28, 2017
How Anthem's new PBM will impact pharma
Nov. 28, 2017
Regeneron scraps another Eylea combo
Nov. 27, 2017
AmerisourceBergen hands over another $625M for manufacturing violations
Nov. 22, 2017
FDA pushes for more abuse-deterrent opioid generics
Nov. 21, 2017
Ardelyx scraps late-stage drug in another pipeline setback
Nov. 21, 2017
Galapagos continues in Vertex's shadow
Nov. 20, 2017
FDA releases its blistering Lupin warning letter
Nov. 16, 2017
Roche's emicizumab wins US approval, threatening shake-up for hemophilia market
Nov. 16, 2017
Mirati reroutes resources to I/O combo, KRAS programs
Nov. 16, 2017
Digital Abilify pill secures first-of-its-kind FDA approval
Nov. 14, 2017
Argos finds silver lining for I/O candidate
Nov. 13, 2017
Novartis' eye drug clearly works, but edging out Eylea won't be easy
Nov. 13, 2017
Ocrevus, Mvasi and 8 other drugs get CHMP go-ahead
Nov. 10, 2017
Lupin reeling after double whammy warning letter
Nov. 8, 2017
Alkermes defends promotion of its opioid dependence drug
Nov. 8, 2017
Ohio voters knock down drug pricing initiative
Nov. 8, 2017
Takeda pursuing needle-free delivery for its top-selling biologic
Nov. 8, 2017
Endo faces more Opana backlash, this time with Kentucky lawsuit
Nov. 7, 2017
Valeant hands Sprout back to former owners
Nov. 6, 2017
Mallinckrodt continues pipeline revamp with Ocera buy
Nov. 3, 2017
Shire moves Cinryze production in-house as manufacturing problems persist
Nov. 2, 2017
Boehringer's NASH dash gets a boost from Dicerna
Nov. 2, 2017
MSF inks deals for lower-cost hep C treatments
Nov. 1, 2017
Allergan draws up battle plans as Restasis, other drugs face patent expiries
Nov. 1, 2017
Sanofi passes on Parkinson's option, crushing Voyager's shares
Oct. 31, 2017
Barriers remain for a drug industry ready to blossom in Brazil
Oct. 30, 2017
AstraZeneca hands Mereo rights to lung drug
Oct. 30, 2017
AbbVie's anti-inflammatories key to growth
Oct. 27, 2017
What to expect from the rest of pharma's earnings
Oct. 26, 2017
Recipharm's serialization push continues with Lisbon facility
Oct. 26, 2017
Slow Otezla growth dampens Celgene's long-term prospects
Oct. 26, 2017
AbbVie taps Alector for deeper dive into Alzheimer's
Oct. 25, 2017
Expanded label opens new market for Alexion's Soliris
Oct. 24, 2017
Biogen doubling down on aducanumab
Oct. 24, 2017
US Spinraza sales cause concern among Biogen investors
Oct. 24, 2017
Global Blood abandons IPF indication after multiple trial letdowns
Oct. 23, 2017
What's next for biopharma Q3 earnings
Oct. 20, 2017
Celgene calls it quits on expensive Crohn's drug
Oct. 20, 2017
With generics market calling, Cambrex outfits Milan facility
Oct. 19, 2017
Scangos' new biotech tackling infectious disease
Oct. 19, 2017
Anthem leaves Express Scripts behind to roll out its own PBM
Oct. 18, 2017
Ignyta lifts off on cancer drug's best-in-class potential
Oct. 18, 2017
MassBio: Massachusetts edges out California as #1 biotech hub
Oct. 17, 2017
Roche kicks antibiotic development into Warp Drive
Oct. 16, 2017
Trevena cuts workforce 30% to free up cash
Oct. 13, 2017
What Q3 earnings will look like for 5 pharma giants
Oct. 13, 2017
Biocon manufacturing problems stall another one of its biosimilars
Oct. 12, 2017
FDA rejection blocks another AcelRx drug from US market
Oct. 12, 2017
Generon moving ahead with Phase 3 trial following SPA
Oct. 11, 2017
Express Scripts drops $3.6B for healthcare management company
Oct. 10, 2017
AbbVie solidifies its I/O pipeline with Turnstone deal
Oct. 10, 2017
Bayer, J&J pull the plug on large Xarelto study
Oct. 9, 2017
What keeps pharma execs up at night? Apparently a lot, says new report
Oct. 6, 2017
Lonza snatches Shire facility as biologics manufacturing rakes in returns
Oct. 5, 2017
Motif delivers more strong data on its antibiotic
Oct. 5, 2017
Allergan to Congress: The IPR system needs fixing
Oct. 4, 2017
Amgen digs deeper in I/O with CytomX deal
Oct. 4, 2017
RedHill reports positive Bekinda data, but investors wary
Oct. 3, 2017
FDA looking to clear path to market for complex generics
Oct. 2, 2017
Ablynx prepares path for lead drug after positive late-stage results
Oct. 2, 2017
Lilly's abema gets FDA OK, setting it up for blockbuster status
Sept. 29, 2017
AmerisourceBergen hands over $260M for a decade of illegal drug manufacturing
Sept. 28, 2017
AbbVie, Amgen reach a deal on Humira biosimilar
Sept. 28, 2017
What does venture capital look for when investing in biopharma?
Sept. 26, 2017
Acer jumps on 7-year-old data
Sept. 25, 2017
Intellipharmaceutics receives painful FDA rejection
Sept. 25, 2017
Allergan touts new data from failed NASH study
Sept. 22, 2017
Korean drugmaker used employees to test potentially harmful ointment, FDA says
Sept. 21, 2017
Fortune's Most Powerful Women list stresses gender gap in pharma
Sept. 21, 2017
Judge denies PhRMA, BIO jab at Nevada law
Sept. 20, 2017
Split adcomm vote leaves Pfizer's Sutent in limbo
Sept. 19, 2017
Teva offloads the rest of its women's health business for $1.4B
Sept. 19, 2017
How to optimize pharma sales forces in a changing marketplace
Sept. 18, 2017
Ultragenyx trying to snag Regenxbio's takeover target
Sept. 18, 2017
Bayer's PI3K inhibitor secures FDA approval
Sept. 15, 2017
Fujifilm opens new mammalian cell facility
Sept. 14, 2017
Bristol, Roche tap Halozyme for tech platform
Sept. 14, 2017
Onxeo finds a partner to progress its cancer medication
Sept. 13, 2017
FDA clears orphan drug backlog ahead of schedule
Sept. 12, 2017
Alexion cuts 20% of its workforce in latest restructuring
Sept. 12, 2017
Teva fills top spot with Lundbeck CEO
Sept. 11, 2017
J&J moves away from hep C due to rival drugmakers' cures
Sept. 11, 2017
Pfizer's EpiPen manufacturer warned by FDA
Sept. 8, 2017
NewLink surges on fresh indoximod data
Sept. 8, 2017
Integration a key focus of FDA's new drug review model
Sept. 7, 2017
Alnylam pauses clinical trials of hemophilia drug after patient death
Sept. 7, 2017
Mallinckrodt tumbles after judge invalidates Inomax patents
Sept. 6, 2017
Bioverativ and Bicycle keep rare disease deals rolling
Sept. 6, 2017
Acorda builds its defense against potential takeover
Sept. 1, 2017
FDA hits yet another Indian drugmaker with warning letter
Aug. 31, 2017
FDA issues second refuse-to-file letter in a week, this time to SteadyMed
Aug. 31, 2017
Aveo wins European approval for cancer drug, triggering milestone payment
Aug. 30, 2017
Otonomy stock crumbles as the company sidelines a key pipeline asset
Aug. 30, 2017
Celgene pays high upfront to extend deal with Forma
Aug. 29, 2017
Jazz, ImmunoGen partner on hematology, oncology drug development
Aug. 29, 2017
Boehringer gains approval for second Humira biosimilar in US
Aug. 29, 2017
Novo's Victoza approved for CV benefit
Aug. 28, 2017
Adamas Parkinson's drug gains FDA approval
Aug. 25, 2017
US, EU advance collaboration efforts on manufacturing
Aug. 24, 2017
Novo manufacturing subsidiary completes Budapest expansion
Aug. 24, 2017
AstraZeneca touts Brilinta CV benefit with new analysis
Aug. 24, 2017
Ultragenyx shelves genetic disease drug after trial failure
Aug. 23, 2017
Novogen irons out Phase 2 plans for brain cancer candidate
Aug. 22, 2017
Cardiome shaken by FDA no-go on heart drug refiling
Aug. 22, 2017
Mylan finalizes $465M settlement for EpiPen
Aug. 17, 2017
FDA flags drugmaker's testing of potentially poisonous powders
Aug. 17, 2017
Novo bests Lilly in diabetes trial, but will that lead to market advantage?
Aug. 17, 2017
Alexion bolsters Soliris patent defense
Aug. 16, 2017
Lexicon's diabetes drug continues to deliver in the clinic
Aug. 15, 2017
Take two: Portola's reversal agent secures FDA review
Aug. 15, 2017
5 Trends influencing drug pricing
Aug. 14, 2017
GSK drops two Ionis drugs in pipeline revamp
Aug. 11, 2017
England starts prioritizing patients amid global hep B vaccine shortage
Aug. 10, 2017
Galapagos' new data is good, but how much weight does it carry?
Aug. 10, 2017
Opioid drugmakers may have to slash production under new DEA proposal
Aug. 9, 2017
Melinta grows pipeline through reverse merger with Cempra
Aug. 9, 2017
Esperion hits a homer with new cholesterol data
Aug. 8, 2017
Placebo response dulls otherwise shiny results for Gemphire drug
Aug. 7, 2017
Dynavax dips as its hep B drug faces another setback
Aug. 4, 2017
Closing Claris deal, Baxter set to invest in three new plants
Aug. 3, 2017
So far, so good for Spark in hemophilia A
Aug. 3, 2017
As Roche wades biosimilar waters, more competitors circle Herceptin
Aug. 2, 2017
23andMe, Lundbeck unveil mega investigation of genetics' role in depression
Aug. 2, 2017
Idhifa approval furthers Celgene's diversification goals
Aug. 1, 2017
Puma's early Nerlynx launch raises doubts of a takeover
Aug. 1, 2017
Bristol-Myers, Clovis ink industry's latest PARP deal
Aug. 1, 2017
LabCorp strengthens its CRO standing with $1.2B Chiltern acquisition
July 31, 2017
Alexion leaves Moderna, others behind in R&D shake-up
July 28, 2017
Tesaro lands licensing, supply agreements for Zejula
July 27, 2017
Pharma buoys Bayer, but US market presents a problem
July 27, 2017
Quark wins in Phase 2, raising the stakes for RNAi
July 27, 2017
GSK gets go-ahead for new Benlysta formulation
July 26, 2017
Celgene pays $280M to make fraud allegations go away
July 26, 2017
J&J reports positive results for HIV regimen
July 25, 2017
Lilly, Incyte likely won't resubmit baricitinib until 2019
July 25, 2017
Keytruda failure another setback for PD-1/L1 class
July 25, 2017
Mitsubishi Tanabe to acquire NeuroDerm for $1.1B
July 24, 2017
5 orphan drugs receive EMA thumbs-up
July 21, 2017
May day: Amgen, Novartis lock down lead for CGRP
July 21, 2017
GSK to ax hundreds of jobs through manufacturing shuffle
July 20, 2017
Ironwood touts positive data, but investors aren't sold
July 20, 2017
BiondVax grows vaccine production with new facility
July 19, 2017
PhRMA finally talks drug pricing in new campaign
July 19, 2017
Positive triple combo data sets up Vertex for big growth
July 19, 2017
Sarepta, BioMarin iron out Exondys 51 patent terms
July 18, 2017
J&J: Remicade holding up better than expected
July 18, 2017
New data from Alzheon shows long-term benefit for Alzheimer's
July 17, 2017
What do we know about the amyloid theory for Alzheimer's?
July 17, 2017
Clinical hold still in effect for Repros' oral drug
July 17, 2017
J&J's Tremfya approved, further crowding IL-inhibitor market
July 14, 2017
Vistin hands partner its opioid, CMO businesses
July 13, 2017
Parkinson's drug Xadago launches in US
July 12, 2017
Manufacturing problems once again stall Ocular's Dextenza
July 12, 2017
Arena pumps out positive results for hypertension drug
July 10, 2017
Novartis hits pause on Fovista agreement
July 10, 2017
Biotech IPOs more than double in Q2
July 7, 2017
FDA issues warning letter to Chinese heparin maker
July 6, 2017
Oxford BioMedica, Novartis link up on CAR-T drug production
July 6, 2017
Amid industry-wide pricing backlash, Vertex raises Orkambi cost
July 5, 2017
Kaléo launches counterclaims against Express Scripts
July 5, 2017
Interleukin Genetics slashes workforce, explores options
July 5, 2017
Alkermes needs to prove safety to succeed with 3831
June 30, 2017
$$$ bountiful for biotech: Atlas raises $350M in latest fund
June 29, 2017
Janssen gets EU nod for continuous manufacturing
June 29, 2017
Gemphire's cholesterol drug shows promise in Phase 2
June 29, 2017
FDA's first steps in drug competition plan: get more generics approved
June 28, 2017
Early results show promise for Ra's rare disease drug
June 28, 2017
Esperion locks down regulatory pathway for cholesterol combo
June 27, 2017
Clarus resubmits oral hormone therapy to FDA
June 27, 2017
Roche's could-be hemophilia blockbuster scores in clinic
June 26, 2017
Novartis anti-inflammatory drug locks down landmark results in CV study
June 22, 2017
Shire's ADHD drug secures FDA OK
June 21, 2017
Pricing pressures lower drug sales forecasts, new report finds
June 21, 2017
Novartis eyes Regeneron's blockbuster Eylea franchise
June 20, 2017
Safety concerns sideline Seattle Genetics' cancer candidate
June 19, 2017
Biotechs waded a storm in 2016, but can they stay the course?
June 19, 2017
EpiPen alternative Symjepi gets FDA OK
June 16, 2017
New deal should help Baxter speed up generic injectables development
June 15, 2017
Pfizer, Roche, Aspen under investigation for cancer drug pricing
June 14, 2017
Report: Pharma spend helps push medical costs up
June 14, 2017
J&J, Pfizer, Merck sit atop Fortune's 500 for pharma
June 13, 2017
J&J's Invokana lowers CV risk, but by enough to compete?
June 13, 2017
5 Trends affecting gene therapy development
June 12, 2017
Regulus reports a trio of pipeline setbacks
June 12, 2017
Lilly preps galcanezumab for 2017 filing
June 10, 2017
AMRI valued at $930M in takeout offer
June 8, 2017
Lilly drops $55M for access to new class of diabetes drugs
June 8, 2017
AbbVie's JAK-1 inhibitor notches Phase 3 win in RA
June 8, 2017
Remodeled drug pricing bill likely to get Nevada Gov.'s signature
June 7, 2017
Jazz strikes positive tone for sleep drug following late-stage hits
June 7, 2017
ASCO17: Chi-Med, Lilly tout cancer med's efficacy in colorectal setting
June 6, 2017
ASCO17: J&J seeks label expansion for Zytiga
June 5, 2017
GSK uses priority voucher to file HIV combo
June 2, 2017
AbbVie, Novo, Takeda have best reputations in pharma, new study finds
June 2, 2017
Merck adding more than 300 new jobs to Irish manufacturing plants
June 1, 2017
Lilly's Strattera faces first wave of generic competition
May 31, 2017
Maryland Gov. allows drug price gouging bill to become law
May 31, 2017
NLS touts Mazindol's efficacy as it takes on ADHD market
May 31, 2017
J&J puts $1B on the line for success of Protagonist drug
May 30, 2017
Merck, UnitedHealth explore improving value-based contracts
May 26, 2017
FDA highlights threat bacteria poses to water-based products
May 25, 2017
Novartis axing 250 US positions in data operations move
May 25, 2017
Merck's Keytruda gets first nod in genetically-defective tumors
May 24, 2017
Bioverativ buys True North, and may forge ahead with more rare disease M&A
May 23, 2017
Investors claw for Puma shares despite questions from FDA adcomm
May 22, 2017
EMA recommends 11 drugs for approval in May meeting
May 22, 2017
Do patients understand the risk of reshaping a genome?
May 19, 2017
Lilly, United extend Adcirca licensing pact
May 19, 2017
The 'Amazon.com for scientists' just raised $24M
May 18, 2017
Shire's angioedema drug scores in Phase 3
May 18, 2017
Otsuka buys Japanese license to Teva's migraine drug
May 17, 2017
J&J, Abbott, Lilly lead pharma in diversity, says report
May 16, 2017
Synlogic goes public through merger with failed Mirna
May 16, 2017
Minerva's schizophrenia drug heads to late stages
May 16, 2017
Biogen buys stroke drug Cirara, further diversifying neuro pipeline
May 15, 2017
Solutions to clinical trial adherence remain elusive
May 15, 2017
Horizon dives into eye treatments with River Visions acquisition
May 12, 2017
Interim results from Capricor's ALLSTAR trial were anything but
May 12, 2017
InVentiv Health, INC Research merger creates top 3 CRO
May 11, 2017
Parexel cutting up to 1,200 jobs, moving positions to 'lower-cost locations'
May 11, 2017
J&J discloses DOJ investigations into marketing, advisory practices
May 10, 2017
AbbVie's JAK-1 inhibitor hits the mark in Crohn's disease
May 10, 2017
Allergan defends threatened franchises, but says 'no large M&A'
May 9, 2017
Express Scripts, GoodRx roll out cost savings program
May 8, 2017
Novartis pushes further into pain with Durect deal
May 8, 2017
Bioverativ beats consensus, raising hopes it can handle looming competition
May 4, 2017
Dr. Reddy's manufacturing facility flagged for procedural problems
May 4, 2017
Payer, consumer pushback expected to dampen drug spending growth
May 4, 2017
Healthcare costs take center stage at LLS roundtable
May 3, 2017
Shire conservative as it navigates Baxalta integration
May 3, 2017
Late-stage failure puts an end to Aeterna Zentaris' lead therapy
May 2, 2017
Shire commits up to $535M for Parion's dry eye drug
May 1, 2017
FDA gives thumbs up to Takeda's lung cancer drug
May 1, 2017
Q1 Earnings Preview: Gilead, Merck, Pfizer, Allergan
May 1, 2017
Alexion's earnings signal a turnaround, but how will that pan out?
April 28, 2017
Lonza cites issues at MD plant for 'softer' Q1 performance
April 27, 2017
Celgene highlights MS drug in diversification push
April 27, 2017
Q1 Earnings Preview: AbbVie, AstraZeneca, BMS, Celgene, Roche, Sanofi
April 26, 2017
Biogen underscores Ocrevus' threat to MS revenues
April 25, 2017
Biogen touts stronger-than-expected rollout for Spinraza
April 25, 2017
Lilly's abemaciclib hits mark in MONARCH 3
April 24, 2017
Q1 Earnings Preview: Novartis, Lilly, Biogen, GSK, Amgen
April 24, 2017
Valeant prices psoriasis drug at $42K per year
April 21, 2017
FDA explains why it rejected AstraZeneca's ZS-9
April 20, 2017
Fujifilm invests $130M in manufacturing expansions
April 20, 2017
AbbVie's PARP inhibitor fails two late-stage cancer trials
April 20, 2017
Novartis CAR-T candidate clinches breakthrough designation
April 19, 2017
CytRx set to file cancer drug NDA
April 19, 2017
Allergan, Novartis ink NASH partnership
April 18, 2017
OncoMed hit with another mid-stage failure
April 17, 2017
In more bad news, Mylan receives CRL for Indian facility
April 13, 2017
Biogen, Roche ink deals with Bristol for rare disease drugs
April 13, 2017
Biopharma IPOs sluggish in Q1. Will that continue?
April 13, 2017
Gilead works on lifecycle management for Sovaldi as Hep C franchise wanes
April 12, 2017
Neurocrine's Ingrezza secures FDA approval
April 12, 2017
Maryland general assembly sends drug price gouging bill to gov.'s desk
April 10, 2017
OncoMed slammed by fizzled Bayer deal, Phase 2 failure
April 10, 2017
Clinical trial enrollment gets harder as patient populations shrink
April 10, 2017
Novartis licenses bite-sized biotech's dry eye drug
April 7, 2017
Dr. Reddy's hit with another Form 483
April 6, 2017
Mallinckrodt exits PhRMA before new rules take hold
April 6, 2017
Mallinckrodt settles investigations into suspicious opioid orders
April 5, 2017
RedHill acquires rights to medical food from Entera Health
April 5, 2017
AACR: Biden touts Moonshot success, questions Trump
April 3, 2017
Astellas buys Ogeda in deal worth up to $850M
April 3, 2017
Novartis ordered to hand over documents in kickback lawsuit
March 31, 2017
Novartis, Aurobindo drugs hit by EMA-advised suspensions
March 30, 2017
Karyopharm shakes off clinical hold for lead cancer med
March 30, 2017
Legwork leaves Sanofi, Regeneron confident in Dupixent uptake
March 29, 2017
Depomed appoints new CEO, board members at activist investor's request
March 29, 2017
Sanofi, Regeneron's eczema drug Dupixent gains FDA approval
March 28, 2017
Cempra pulls European marketing application for antibiotic
March 28, 2017
Allergan acne med shines in late-stage trials
March 27, 2017
Insys cannabinoid drug Syndros given Schedule II status
March 24, 2017
FDA bans Divi's Labs plant, dealing another blow to India's quality credibility
March 23, 2017
Ultragenyx's seizure med fails mid-stage trial
March 23, 2017
Life science execs increasingly interested in out-licensing
March 22, 2017
Novartis heart drug fails in Phase 3
March 22, 2017
Sanofi, Regeneron launch preemptive patent strike against Amgen
March 21, 2017
Daré hoping to turn Cerulean from blue to black
March 21, 2017
Bristol-Myers broadens CytomX partnership, spending $200M more
March 20, 2017
Lilly offers up drug pricing details amid ongoing scrutiny of industry
March 20, 2017
FDA hands AstraZeneca's ZS-9 another setback
March 17, 2017
Sun Pharma gets ray of good manufacturing news
March 16, 2017
New $300M venture firm sets sights on young biotechs
March 16, 2017
FDA advisory panel votes against Endo's opioid painkiller
March 15, 2017
Bernie Sanders calls for more broadcast news on drug pricing
March 15, 2017
Alexion to cut R&D, 7% of workforce
March 14, 2017
Investors have high expectations for cannabinoids
March 13, 2017
Retrophin to close Cambridge operations
March 10, 2017
Genentech, Novo, Regeneron make Fortune's list of best places to work
March 9, 2017
Beigene plans $330M biologics facility in China
March 8, 2017
M&A heating up among smaller I/O drugmakers
March 8, 2017
Amgen debuts Repatha ad amid ongoing patent battle
March 7, 2017
FDA lifts trial holds for Seattle Genetics' cancer med
March 7, 2017
PTC files DMD drug in spite of earlier rejection
March 6, 2017
Samsung Bioepis beats AbbVie in UK patent court
March 6, 2017
AstraZeneca, Sanofi partner on infant respiratory drug
March 3, 2017
FDA, EU amendment looks to crack down on duplicate inspections
March 2, 2017
Juno shelves JCAR015, shifts focus to earlier compound
March 1, 2017
Pfizer flagged for more manufacturing issues
March 1, 2017
FDA gives go-ahead to Lexicon's rare disease drug
March 1, 2017
Kite flying high on Zuma-1 data
Feb. 28, 2017
Divestitures, patent expiries loom over Valeant
Feb. 28, 2017
J&J unpacks pricing decisions in new transparency report
Feb. 27, 2017
Bristol, Roche team up with Exelixis on cancer trials
Feb. 27, 2017
Spectrum shareholder accuses company of 'misleading' investors
Feb. 24, 2017
Momenta's Copaxone generic delayed following Pfizer warning letter
Feb. 23, 2017
Cyclacel's lead candidate flops in Phase 3
Feb. 23, 2017
DMC: little promise for Argos cancer therapy
Feb. 22, 2017
Pfizer, Celltrion pushing for interchangeability with Inflectra
Feb. 22, 2017
J&J leads pharma in Fortune's most admired companies list
Feb. 21, 2017
Trevena stock tanks despite positive late-stage results
Feb. 21, 2017
Celgene notches clinical victory for its first MS drug
Feb. 17, 2017
Daiichi, ArQule cancer drug fails in late-stage study
Feb. 17, 2017
Daiichi shutters Japanese plant amid restructuring efforts
Feb. 16, 2017
Baxalta pushes Shire to record revenues
Feb. 16, 2017
Senators call on HHS' Price to fast track Canadian drug imports
Feb. 14, 2017
Sage forges ahead with depression drug after positive Phase 2 results
Feb. 14, 2017
Allergan builds out aesthetics business with $2.5B deal
Feb. 13, 2017
A biomarker could tackle one of worst diseases in sports
Feb. 13, 2017
Seattle Genetics grabs rights to Immunomedics' tumor drug
Feb. 10, 2017
Neurocrine enters licensing deal for Parkinson's drug
Feb. 10, 2017
Pfizer plans to close Australian manufacturing plant
Feb. 9, 2017
GSK well-positioned to weather tax changes, execs say
Feb. 8, 2017
Amgen secures FDA approval for hormone drug
Feb. 8, 2017
Allergan talks tax reform, drug pricing
Feb. 8, 2017
Perrigo restructures board in deal with activist investor
Feb. 7, 2017
Express Scripts says branded drug prices rose nearly 11% last year
Feb. 6, 2017
Eli Lilly plans to cut 200 R&D jobs
Feb. 6, 2017
Biotech IPOs off to better start in 2017
Feb. 3, 2017
Merck's Perlmutter: Cancer not one size fits all
Feb. 2, 2017
Merck unveils new Keytruda DTC ad
Feb. 1, 2017
Catabasis' DMD drug fails in Phase 2
Feb. 1, 2017
Mallinckrodt unloads spinal drug unit
Jan. 31, 2017
Amgen's Humira biosim clears EMA regulatory hurdle
Jan. 30, 2017
Humira's future remains biggest worry for AbbVie investors
Jan. 27, 2017
Earnings Preview: Merck set to solidify I/O lead, Sanofi still looking for deals and more
Jan. 26, 2017
FDA slams Jazz CMO for continued violations
Jan. 26, 2017
Celgene doubling down on pipeline expansion in 2017
Jan. 26, 2017
Payers balk at price of EpiPen rival
Jan. 25, 2017
Q4 was a mixed bag for pharma. Will 2017 be the same?
Jan. 25, 2017
Lilly turns to pain after solanezumab failure
Jan. 25, 2017
Merck pays $625M to settle patent battle with Bristol, Ono
Jan. 23, 2017
PhRMA-backed report analyzes 'complex process' of drug pricing
Jan. 19, 2017
Earnings preview: 7 biopharmas to watch
Jan. 19, 2017
Neurocrine's Tourette drug misses mark in mid-stage trial
Jan. 19, 2017
Evotec creates fibrotic disease company through new partnership
Jan. 19, 2017
Lilly acquires CoLucid, strengthening neuro pipeline
Jan. 18, 2017
Trial failure deals harsh blow to Alcobra
Jan. 17, 2017
Allergan moves toward NDA after uterine fibroid drug's success
Jan. 17, 2017
Daiichi closes India facility in continued R&D overhaul
Jan. 12, 2017
Vertex hands off cancer drugs to Merck KGaA
Jan. 11, 2017
Sarepta signals strong start for Exondys 51
Jan. 11, 2017
Kite inks China, Japan deals ahead of possible CAR-T drug approval
Jan. 10, 2017
Report: Oncology, profitable drugs move to market faster, patent exclusivity shrinking
Jan. 9, 2017
Pharma M&A may see 'banner year' in 2017, EY predicts
Jan. 9, 2017
JPM: Takeda acquires Ariad in $5.2B deal
Jan. 9, 2017
Dynavax axes staff in pivot toward I/O
Jan. 6, 2017
FDA releases guidance on electronic drug applications
Jan. 5, 2017
Halozyme unveils mid-stage data for pancreatic cancer drug
Jan. 5, 2017
Ocular boasts more positive data for Dextenza
Jan. 5, 2017
Sanofi asked to pull vaccine ads in the Philippines
Jan. 4, 2017
Inotek shares freefall after glaucoma drug failure
Jan. 4, 2017
RedHill, Concordia team up to market IBS drug
Jan. 3, 2017
7 takeover targets to look out for in 2017
Jan. 3, 2017
A look back: Top stories of 2016
Dec. 26, 2016
Novartis, Sun Pharma enter deal for oncology drug Odomzo
Dec. 23, 2016
Sygnis puts cash to use, acquires C.B.S. Scientific
Dec. 22, 2016
Biotechs line up to tap growing ophthalmics market
Dec. 21, 2016
Novartis buttresses Alcon with Encore Vision takeover
Dec. 21, 2016
Novartis sells US rights to 3 COPD drugs
Dec. 21, 2016
FDA pushes decision on Roche MS drug to March
Dec. 21, 2016
Bristol continues immuno-oncology push in deal with PsiOxus
Dec. 20, 2016
Pfizer's Chantix loses its black box warning
Dec. 19, 2016
Celgene, Evotec team up on neurological treatments
Dec. 16, 2016
Lonza swallows Capsugel in deal worth $5.5B
Dec. 15, 2016
BIO President responds to QuintilesIMS pricing report
Dec. 14, 2016
Moody's signals bigger risks for PBMs amid pricing backlash
Dec. 14, 2016
Grünenthal picks up rights to pain patch from Astellas
Dec. 13, 2016
Centrexion osteoarthritis drug hits its mark in Phase 2
Dec. 13, 2016
Novartis, Ophthotech combo therapy fails in Phase 3
Dec. 12, 2016
AstraZeneca cuts 700 US jobs
Dec. 9, 2016
FDA slaps Spanish API maker with warning letter
Dec. 8, 2016
Endo chops sales force after ditching pain drug
Dec. 8, 2016
J&J, Genentech make Glassdoor's list of best places to work
Dec. 8, 2016
Report: Biosimilars, specialty drugs inversely impact drug spend
Dec. 7, 2016
AstraZeneca touts Tagrisso's edge in lung cancer
Dec. 6, 2016
QuintilesIMS projects slower drug spending growth through 2021
Dec. 5, 2016
Acetylon forms Regenacy ahead of Celgene takeover
Dec. 5, 2016
Roche brings Kapa into partnership with German Merck
Dec. 2, 2016
Report: BioMarin, Bristol, Lilly most undervalued drugmakers
Nov. 30, 2016
Novo Nordisk pulls ad from Breitbart
Nov. 30, 2016
MedImmune, Abpro link up to accelerate antibody development
Nov. 29, 2016
Positive trial results push Santen eye drug toward approval
Nov. 28, 2016
Idera sells licensing rights to shelved autoimmune drug
Nov. 28, 2016
Allergan builds Alzheimer's portfolio with Chase acquisition
Nov. 23, 2016
Walgreens expands partnership providing patient drug reviews
Nov. 22, 2016
Novo, Sanofi get same-day approval for diabetes drug combos
Nov. 22, 2016
Novartis snags sickle cell drug in Selexys acquisition
Nov. 21, 2016
GlobeImmune CEO steps down as partnership with Gilead fizzles
Nov. 18, 2016
Eagle acquires Arsia, moves in on biosimilars
Nov. 17, 2016
Amgen, Novartis tout top-line migraine results
Nov. 16, 2016
FDA issues warning to Supernus for 'misleading' marketing
Nov. 16, 2016
Bristol continues microbiome exploration with Enterome deal
Nov. 16, 2016
UniQure to cut 20% of workforce, revamp pipeline
Nov. 15, 2016
Novavax aims to rebound with restructuring, more trials
Nov. 14, 2016
Gilead's Vemlidy approved for hep B in US, EU
Nov. 11, 2016
RedHill full steam ahead on stomach-illness drug
Nov. 10, 2016
Bristol digs deeper into NASH with Nitto deal
Nov. 10, 2016
Kadmon cuts jobs to conserve cash, pay debt
Nov. 9, 2016
Endo talks pricing, generics market turmoil
Nov. 8, 2016
Lexicon buys Bristol neuro drug
Nov. 8, 2016
Cempra drug narrowly wins support of FDA panel
Nov. 7, 2016
Prop 61: What does it mean for drug prices?
Nov. 4, 2016
Troubled Infinity licenses cancer drug to Verastem
Nov. 3, 2016
Lonza ramps up drug manufacturing with new Swiss facility
Nov. 3, 2016
Cempra stock plummets after FDA raises safety concerns
Nov. 3, 2016
Mitsubishi strengthens arthritis portfolio with TissueGene deal
Nov. 2, 2016
Allergan: More M&A, international expansion
Nov. 2, 2016
Eisai ups investment in Alzheimer's treatments
Oct. 31, 2016
AbbVie upbeat on Humira as biosimilars come barreling in
Oct. 31, 2016
Astellas furthers oncology focus with Ganymed buy
Oct. 28, 2016
Witch's brew? What drugs contain leech and lizard parts
Oct. 28, 2016
Lilly, GSK, Gilead outsourced the most in Q3: report
Oct. 27, 2016
Evotec picks up CRO Cyprotex for $68M
Oct. 27, 2016
Bayer aims to cut costs ahead of Monsanto deal
Oct. 26, 2016
FDA taking a closer look at DTC animation
Oct. 26, 2016
Biogen quiet on new CEO, but signals optimism in Alzheimer's
Oct. 26, 2016
Teva clears submission hurdle for Huntington's drug
Oct. 21, 2016
VBL secures new Israeli manufacturing site
Oct. 20, 2016
Lilly breaks 40-year drought in 1L soft-tissue sarcoma
Oct. 20, 2016
4 US pharma execs make Forbes 400 list
Oct. 19, 2016
J&J optimistic in spite of biosimilar threat
Oct. 18, 2016
Moderna taps Catalent for clinical manufacturing
Oct. 17, 2016
Chinese drugmaker, 3 others warned in FDA letters
Oct. 13, 2016
Regeneron eyes long-lasting Eylea in deal with Ocular
Oct. 13, 2016
Celltrion finds new partner after Pfizer exit
Oct. 6, 2016
Amgen inks latest high price-tag research collaboration
Oct. 4, 2016
10 stories that had the industry talking in Q3
Oct. 3, 2016
Genentech commits $80M upfront in Hanmi licensing deal
Sept. 29, 2016
FDA hits pause on CEL-SCI Phase 3 trial
Sept. 28, 2016

Reach a targeted audience

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 189,000 newsletter subscribers for 21 days.

Post a press release ➔

Select Newsletter: Daily Dive M-F
Select Newsletter: Commercialization Weekly Every Wednesday
Select Newsletter: Gene Therapy Weekly Every Thursday
Select Newsletter: Emerging Biotech Weekly Every Tuesday
Select user consent: By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

Industry Dive is an Informa TechTarget business.

This website is owned and operated by Informa TechTarget, part of a global network that informs, influences and connects the world's technology buyers and sellers. All copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. TechTarget, Inc.'s registered office is 275 Grove St. Newton, MA 02466.

Home
- Pharma
- Biotech
- FDA
- Clinical Trials
- Deals
- Drug Pricing
- Gene Therapy
Deep Dive
Library
Events
Press Releases

Get BioPharma Dive in your inbox

The free newsletter covering the top industry headlines

Select Newsletter: Daily Dive M-F
Select Newsletter: Commercialization Weekly Every Wednesday
Select Newsletter: Gene Therapy Weekly Every Thursday
Select Newsletter: Emerging Biotech Weekly Every Tuesday
Select user consent: By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.